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ABSTRACT 
 
 
The first chapter of this dissertation serves as an introduction to the problem of 
awareness of discrimination based on genetic information in United States’ (U.S.) 
citizens. It also provides the rationale for the development of the three manuscripts to 
study the federal genetic nondiscrimination law, the Genetic Information 
Nondiscrimination Act of 2008 (GINA), leading to conduct of the concept analysis, 
awareness of discrimination based on genetic information, and finally to a pilot research 
study that quantitatively assesses the awareness and knowledge of GINA among nurse 
practitioners (NPs) in South Carolina. 
The second chapter, Manuscript I, is a narrative review of GINA.  The manuscript 
describes the legislative history, provisions and limitations of GINA, along with case 
studies to educate oncology nurses and oncology nurse practitioners on how to apply 
GINA to their patients and families. 
The third chapter, Manuscript II, written after the narrative review, explores the 
concept of awareness of discrimination based on genetic information through an in-depth 
content analysis, using Wilson’s method of concept analysis with case study examples. 
Both Manuscripts I and II were published before healthcare provisions of the Patient 
Protection and Affordable Care Act of 2010 (PPACA) were implemented. 
The fourth chapter, Manuscript III, is a quantitative pilot study, an empirical first 
look that assesses the awareness of GINA among a sample of nurse practitioners in South 
Carolina. This pilot study data collection was also completed before PPACA was 
implemented into healthcare. This manuscript is to be submitted to the Journal of the 
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American Association of Nurse Practitioners which has a defined word limit for 
publication of pilot studies. 
The final chapter of this dissertation is the synthesis of all three manuscripts; 
related to the ethical framework of the entire dissertation, the nursing model and 
conceptual analysis method of the second manuscript and the sociological diffusion 
theory used in the third manuscript.  The final chapter also contains implications for a 
future program of research.  As a result of these manuscripts, it is anticipated that new 
knowledge concerning awareness of discrimination based on genetic information and the 
provisions and limitations of GINA will emerge; that nurses will then disseminate this 
knowledge to other healthcare professionals, patients and their families. 
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CHAPTER ONE  
 
INTRODUCTION 
 
 
In 1990, at the start of the Human Genome Project, project planners prospectively 
acknowledged that decoding the human genome might bring, along with achievements, 
the potential for misuse of genetic information.  The Program Advisory Committee of 
this project established the Ethical, Legal, and Social Implications (ELSI) Working 
Group in 1989 (Norrgard, 2008; Robertson, 2003).  Comprised of genome scientists, 
medical geneticists, ethicists, philosophers and individuals with expertise in the law, as 
well as consumers, one of ELSI’s duties was to develop public and professional policies 
related to researching the human genome and applications of research (Norrgard, 2008)    
Since no one individual has a perfect genetic make-up, all individuals could face 
genetic discrimination at some time in their lives.  The ELSI Working Group, genetic 
health professionals, and researchers realized early on while working on the Human 
Genome Project that genetic discrimination needed to be addressed before results of that 
project could be implemented; that citizens of the United States (U.S.) had “fear factors” 
in regard to personal clinical genetic testing (Lea, 2008).  Individuals were also wary of 
taking part in research studies due to fears that their deoxyribonucleic acid (DNA) 
information might be used against them either in the workplace or/and the health 
insurance arena (National Human Genome Research Institute[NHGRI], 2009). 
Participants in the ELSI Working Group also believed that this fear of discrimination 
based on the individual’s genetic information would diminish the importance and use of 
the Human Genome Project’s genetic discoveries in the healthcare arena. Before the start 
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of the Human Genome Project, the degree of protection in state laws in the U.S. against 
genetic discrimination varied broadly. Thus, a federal law, the Genetic Information 
Nondiscrimination Act of 2008 (GINA), hailed as the first civil rights bill of the 21
st
 
century, was passed and signed into law on May 21, 2008 by President George W. Bush 
to ease these “fear factors” (Norrgard, 2008).  
Healthcare providers need to be aware that genetics/genomics is linked to most of 
the health problems of their patients.   A particular group of these healthcare providers, 
nurse practitioners (NPs), assesses, diagnoses, treats and manages patients with genetic 
diseases in various clinical settings. Therefore NPs, in particular, need to integrate 
knowledge of genetic testing and treatments into their clinical practice (Abel, Horner, 
Tyler & Innerarity, 2005; Lea & Williams, 2002). Besides being aware of the ethical and 
social implications of diagnosing, testing and managing genetic diseases in their patients, 
NPs also need to be aware of the legal implications surrounding the genetic information 
and genetic testing of their patients (Lerman, Croyle, Tercyak, & Hamann, 2002). 
NPs need to integrate their awareness and knowledge, of legal implications 
surrounding genetic testing of their patients, into their clinical practice settings.  Also, 
NPs need to be aware of how their patient’s test results and genetic information can lead 
to discrimination by the health insurance industry and in their patients’ workplaces.  This 
potential knowledge gap of awareness of discrimination based on genetic information and 
awareness of GINA in NPs leads to the overall questions that guide this dissertation: 
1.  What is GINA?  What are the provisions and limitations of GINA?  Why is it 
different from other federal healthcare discrimination laws?  What are the 
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important points in GINA that NPs to be aware of in order to protect 
themselves and their patients? 
2. What exactly is awareness of discrimination based on genetic information?  
How can the concept be operationally defined for NPs to use in their research 
and clinical practice? 
3. Using the answers from Questions 1 and 2, how can the nursing discipline 
assess the extent to which NPs possess awareness of GINA and the concept of 
discrimination based on genetic information in order to advocate effectively 
for their patients and their patients’ families? 
Graduate nursing faculty recognized that current and future NP students should be 
aware of and knowledgeable about healthcare genetics and genomics as they prepared to 
practice in their expanded nursing roles.  These students needed an ethical assessment 
framework to support them to deliver appropriate genetic/genomic healthcare.  Having 
such an ethical assessment framework, essential competencies, integrated into their 
curricula help nursing students develop expert delivery of healthcare, as well as nursing 
research expertise (Lea, 2008). Thus, a consensus panel, made up of leaders in the 
genetic/genomic nursing arena, established the “Essential Genetic and Genomic 
Competencies for Nurses with Graduate Degrees” (Greco, Tinsley, & Siebert, 2011).   
The resultant competencies were modeled after “Essential Nursing Competencies for 
Genetics and Genomics” for baccalaureate nurses, conceptualized from the theoretical 
framework of Rogers’ Diffusion of Innovation Theory (Jenkins & Calzone, 2007).  
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A total of 38 competencies for advance practice nurses were developed in the 
following areas:  risk assessment, genetic education, genetic counseling, genetic testing 
and results interpretation, clinical management of genetic patients and genetic/genomic 
ethical, legal, and social implications (Greco, Tinley, & Seibert, 2011). Appropriate 
competencies suggested from this consensus panel, as well as Rogers’ Diffusion of 
Innovation theory which was the theory used to guide the formulation of essential 
competencies, provide the foundation for the three independent manuscripts comprising 
this dissertation research (Jenkins & Calzone, 2007).  All three manuscripts in this 
dissertation meet, partially or entirely, at least one of the essential competencies for the 
graduate education of NPs.  Commonalities in the three manuscripts focus on awareness 
of discrimination based on genetic information and awareness of GINA when delivering 
competent genetic/genomic nursing care.  These three manuscripts advance the nursing 
discipline’s knowledge concerning genetic/genomic discrimination in patients and 
patients’ families. 
The first manuscript (Chapter 2) is entitled “The Need to Be Aware and Beware 
of the Genetic Information Nondiscrimination Act” (Steck & Eggert, 2011).  This 
narrative review provides genetic/genomic information about GINA to oncology nurses 
and oncology NPs, reflecting the fact that cancer is a genetically-derived disease. It 
discusses the fear of genetic testing by cancer patients, the legislative history of GINA, 
proponents and opponents of GINA, as well as the provisions and limitations of GINA 
that oncology nurses and oncology NPs need to know in order to better advocate for their 
patients and their patients’ families (Steck & Eggert, 2011).  This manuscript specifically 
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meets the competency, “All nurses with graduate degrees in nursing inform health care 
and research policy related to ELSI issues in genetics/genomics” (Greco, Tinley, & 
Siebert, 2011).  
The second manuscript (Chapter 3), entitled “Concept Analysis:  Awareness of 
Discrimination Based on Genetic Information” recognizes how NPs’ attitudes and values 
that are related to genetic/genomic science may affect the care that they provide to their 
patients (Steck, 2012).   This manuscript is based on the statement made by Baldwin 
(2008) that “researchers need to consider what it is they’re researching using concept 
analysis before starting work.” The resulting concept analysis manuscript discusses the 
history of discrimination by registered nurses (RNs) and NPs in regard to not only their 
patients, but also how they discriminate against their peers.  Recent research studies 
demonstrate that RNs and NPs discriminate against their patients and within the nursing 
profession based on race, religion, gender, ethnicity and other social constructs 
(Thornburn Bird, Bogar & Delahanty, 2004; Hocking, 2003; Puhl & Brownell, 2001).  
Thus a concept analysis, epistemically operationalizing the concept of awareness of 
discrimination based on genetic information, was derived in order to be utilized in the 
third manuscript of this dissertation, the quantitative research pilot study. 
  The resultant operational definition of the concept of awareness of 
discrimination based on genetic information, using Wilson’s method of concept analysis, 
is “to know differences against people or distinguish between people based on their 
ancestral, heritable, communicated facts or knowledge” (Steck, 2012).  Wilson’s method 
of concept analysis not only includes a dissection of words used in the concept, but also 
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determines how the resultant operational definition is used in model, contrary, and/or 
borderline cases when an individual is discriminated based on their genetic information.  
This awareness concept can also be applied to an existing nursing theory, in this case, 
Roy’s Adaptation Model.  The concept, awareness of discrimination based on genetic 
information, is an addition to Roy’s holistic view that an individual is made up of inter-
correlated parts, including an individual’s genetic make-up, and possible discrimination 
based on that genetic information or make-up (Phillips, 2010).  The second manuscript 
meets the essential competency, “Nurses with graduate degrees need to maintain a solid 
foundation in genetics/genomics to provide safe and competent care to clients” (Greco, 
Tinley & Seibert, 2011).  
The third manuscript (Chapter 4) is entitled “Awareness of the Genetic 
Information Nondiscrimination Act of 2008 in Nurse Practitioners:  A Pilot Study.”   The 
purpose of this exploratory pilot study was to assess the awareness and knowledge of 
GINA among NPs in South Carolina utilizing Rogers’ Diffusion of Innovations to as a 
theoretical basis to guide the study (Macleod-Clark & Hockey, 1989).  Thus, this third 
manuscript is initial vital step to meeting the competency in the ethical framework, 
“Nurses prepared at the doctoral level are expected to provide leadership in the conduct 
of research and translation of genetic/genomic findings into practice” (Greco, Tinsley, & 
Siebert, 2011). 
  The third manuscript begins with a literature review of peer-reviewed published 
research studies that assess the awareness and/or knowledge of GINA among consumers, 
genetic counselors and/or physicians. No research study in the literature review assessed 
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the awareness and/or knowledge of GINA among nurse practitioners, particularly those 
NPs in specialized clinical practice that utilize genetic testing, as well as those newly-
graduated NPs who have had healthcare genetics integrated into their graduate 
curriculum after GINA became law.  Thus, a need was identified to measure the 
awareness and knowledge of GINA among NPs and to close a gap in the literature.  
The following descriptive research study, guided by Rogers’ Diffusion of 
Innovation theory, utilized descriptive statistics and variable selection methods to assess 
awareness of GINA, by utilizing a pilot study sample.  A questionnaire was constructed, 
using a focus group and an expert panel, to assess the awareness and knowledge of 
GINA, using a volunteer sample of NPs from South Carolina.  The results from this pilot 
study will be used to identify variables from Rogers’ Diffusion of Innovation theory that 
play roles in the awareness and knowledge of GINA in NPs in South Carolina.  Steps 
used to create the questionnaire, from its theoretical construct development to its 
corresponding item generation and through to the questionnaire’s pilot testing are 
specifically and thoroughly addressed in an additional manuscript to be submitted for 
publication (Table 1.1). 
 
 
 
 
 
 
 8 
Table 1.1  
Questionnaire Development Steps 
Step Purpose Methods 
1. Determine what is 
to be measured 
Select and study a well-grounded 
theory to develop hypotheses, 
constructs 
and concepts related to the 
phenomenon being measured 
Review of Rogers’ Diffusion of 
Innovations theory which explains 
characteristics that influence a NP to have 
awareness-knowledge of GINA.  
Theoretical components to be synthesized 
into constructs/concepts in order to 
generate questionnaire items. 
2. Generate an item 
pool from review 
of literature 
To propose self-report/response 
data collection items that facilitate 
responses representing variables 
that influence awareness of GINA. 
Draft items for scale responses according 
to constructs/concepts of the theory. 
asking level of importance by dissertation 
committee members in assessing 
awareness-knowledge of GINA in NPs 
3. Determine the 
format for 
measurement 
To determine what scales are most 
compatible with the theory: 
constructs and concepts 
Occurs simultaneously with generation of 
questionnaire items so that the two steps 
are compatible 
4. Initial 
questionnaire item 
pool reviewed by 
experts 
To establish content validity Nine nurse practitioners with genetic 
expertise scored the questionnaire items 
for content validity  index to prepare 
questionnaire for transfer to Qualtrics® 
survey software for field testing 
5. Consider  
inclusion of 
validation items/ 
field test revised 
questionnaire 
Test reliability in a small sample 
Interact with subjects regarding 
readability, item burden and 
testing problems 
Refined questionnaire items on 
Qualtrics® survey software. Utilize ten 
Clemson University NPs, not possessing 
genetic expertise and not included in the 
sample population, to identify 
questionnaire administration problems. 
6. Administer final 
revised online 
questionnaire to 
pilot sample 
 
To evaluate for construct validity 
and reliability 
Use findings to evaluate future 
development steps 
 
 
Utilize pilot sample to include members 
of two SC NP associations 
Cronbach’s alpha for reliability 
Descriptive statistics for construct validity 
 
 9 
 Chapter 5 synthesizes the collective conclusions from the three manuscripts to 
make this dissertation a complete body of work.  Implicit knowledge gaps from the three 
manuscripts are identified, including a plan for future research concerning the awareness 
of discrimination based on genetic information, as well as the awareness and knowledge 
of GINA among NPs.  The primary goal of this body of work is to analyze the problem of 
discrimination based on genetic information, by formulating an operational definition of 
this concept that nurses may use in their clinical practice, and empirically assessing NPs’ 
awareness and knowledge of GINA. A secondary gain is to advance the discipline of 
nursing’s knowledge of healthcare genetics through use of Rogers’ Diffusion of 
Innovations theory, researching what variables lead NPs to adopt of a new innovation, 
GINA. A tertiary gain is to demonstrate how these three manuscripts incorporate 
essential competencies for graduate nurses to advance nursing research.  
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CHAPTER TWO 
THE NEED TO BE AWARE AND BEWARE OF THE GENETIC  
 
INFORMATION NONDISCRIMINATION ACT 
 
(Submitted 9/8/2010, accepted for publication 1/31/2011, published in the 6/2011 issue of 
the Clinical Journal of Oncology Nursing) 
 
 
Abstract 
Genetic advancements during the latter part of the 20th century and the beginning 
of the 21st century have presented individuals, the medical community, and legislators at 
state and federal levels, with numerous genetic discrimination predicaments.  Oncology 
nurses need to be knowledgeable about GINA (The Genetic Information 
Nondiscrimination Act of 2008) and its applications to clinical practice. GINA is the first 
federal law passed to protect United States’ citizens with inherited disorders from being 
treated unfairly due to their genetic make-up.  Understanding the legislation known as 
GINA, including how it modifies existing federal laws governing health insurance 
coverage and employment discrimination, can assist oncology nurses in providing 
important education and advocating for their patients and extended families.    Federal 
agencies that govern and enforce GINA’s provisions will be identified.  Case situations 
are included to demonstrate how to apply information concerning GINA to the oncology 
patient/family considering or having already completed genetic testing.  Concerns about 
missing elements in GINA and their impact will also be addressed, so oncology nurses 
can offer colleagues and patients an explanation of the pros and cons of the new law. 
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Since GINA was completely enacted in 2009; oncology nurses need to be aware 
of GINA’s provisions and its associated shortcomings in order to assist their patients and 
the families to make informed decisions regarding genetic testing.  Privacy of genetic 
information is a timely issue, though not easy to understand, so provisions of GINA need 
to addressed and carefully evaluated.  
Introduction and Statement of the Problem 
Genetic testing is used to identify genetic propensities to predict risk for future 
disease, diagnose genetic conditions with guidance for treatment decisions, provide 
information for reproductive decisions, profile individuals or their tumors, for selection 
of medication and/or personalizing medication dosage for best results (Genetics & Public 
Policy Center [GPPC], 2008). There are now more than 1,500 genetic tests available.  
According to Dr. Francis Collins, Past-Director of the National Human Genome Research 
Institute and current Director of the National Institutes of Health, “Many people have 
been unwilling to participate in medical research or be tested clinically, even when at 
substantial risk of serious disease, because of fears their genetic information might be 
used against them” (The Threat of Genetic Discrimination, 2007). Because of this fear, 
many patients who have obtained genetic testing have done so anonymously or under 
assumed names due to concerns about discrimination from employers and insurance 
companies.   These patients face additional financial strain if they choose to pay for their 
genetic tests out-of-pocket, since genetic testing and counseling can cost thousands of 
dollars for testing a single gene mutation, whether a change in the genetic code is present 
or not (U.S House of Representatives, 2007). 
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Background 
Genetic discrimination can occur in multiple situations.  Of special concern is 
when employers have used genetic information to deny employment, discharge current 
employees, or deny workers’ compensation benefits.  One well-known case of genetic 
discrimination concerns Lawrence-Berkeley Laboratories, a state and federal research 
institution.  Between 1968 and 1993, this institution included tests for syphilis, sickle cell 
genetic markers and pregnancy in its pre-employment and annual medical examinations 
without the employees’ knowledge or consent.  Employees were told only that they were 
“having cholesterol testing.”  The use of testing without informed consent, was revealed 
and condemned in a major lawsuit decision in 1998, in which the court held that the 
employer’s actions constituted the “most basic violation possible” of the employee’s 
rights to privacy guaranteed under the Constitution (Coalition for Genetic Fairness 
[CGF], 2008).  
In a retrospective, cohort study conducted by Armstrong et al. (2003), fear of 
genetic discrimination played an important factor in the decision whether to undergo 
genetic testing to determine familial breast cancer. The researchers found over half the 
636 women who had undergone genetic counseling described fear of genetic 
discrimination as a reason for refusing genetic testing. The women who refused testing 
expressed concerns about life insurance discrimination if their genetic test results were 
made available to insurance companies (Armstrong et al., 2003). 
Fear of genetic discrimination can also cause adverse financial impacts on 
individuals and the health care system even though there is the potential for saving health 
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care dollars. The early detection and prevention via genetic testing results could lessen 
the financial costs caused by late diagnosis and chronic illnesses like cancer.  Avoidance 
of genetic tests due to discrimination fears may cause thousands of dollars in additional 
detection and treatment health care costs.  Individuals treated at a later stage of cancer 
often face financial crisis; increased cost-sharing and out-of-pocket medical bills that 
create significant medical debt.  According to one not-for-profit organization, the Genetic 
Alliance, dedicated to promoting health care for persons with genetic disorders, medical 
debt is a leading source of personal financial bankruptcy in the United States, leading to 
home foreclosures and possible financial difficulties (Genetic Alliance [GA], 2008). Lost 
income during extended illnesses, like cancer, can also become an issue.  Some 
individuals, such as those at high risk to develop an inherited cancer syndrome that 
receive and use genetic testing information results without fear of discrimination, may 
prevent personal financial difficulties. Thus, Americans can benefit from personal genetic 
testing if they know that their health insurance and employment will not be at risk 
because of positive genetic test results.   
While GINA offers some protection against genetic discrimination, it is 
incomplete protection.  Many people may have to choose between undergoing genetic 
testing that could lead to early detection and prevention of a cancer or forgoing genetic 
testing to economically protect their families from adverse genetic discrimination 
(Rothstein, 2008).  
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Need for GINA 
Many Americans, while optimistic that their genetic information could improve 
their health, also express concern that the same genetic information could be used to 
discriminate against them.  They fear that health insurers would refuse to either insure 
them or would cancel existing health insurance if they are found to be predisposed to 
future onset of a genetic disease.  Similarly, Americans fear that employers would only 
retain or hire those individuals who are not pre-disposed to genetic disease in order to 
have healthy, productive employees.  As a result of these fears, most Americans, in 
addition to scientists and health advocacy groups expressed a need for federal legislation 
to protect all Americans from genetic discrimination (National Human Genome Research 
Institute [NHGRI], 20). 
Federal nondiscrimination legislation was proposed as a solution to prevent cases 
of genetic discrimination previously documented and to prevent fears of future genetic 
discrimination by employers and insurance companies.  Individuals realized the privacy 
protections of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) 
did not prohibit health insurers from requiring genetic testing or from denying coverage 
based on genotypic information (CGF, 2008).  On the state level, a majority of state 
legislatures responded to concerns of individual genetic discrimination by health insurers, 
employers or both, but states’ laws did not provide uniform protections to American 
families at the national level.  Unfortunately, the patchwork of state laws left some 
individuals vulnerable to genetic discrimination.  One provision of GINA is that it would 
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not preempt more protective state laws so that in any situation an individual would 
receive maximum protection allowed by federal and state laws (Rothstein, 2008).   
Currently, 18 states have no genetic privacy laws.   Seventeen states require 
signed informed consent from an individual before insurers or employers can request a 
genetic test or genetic information can be obtained   Genetic information is considered 
personal property in Alaska, Colorado, Florida, Georgia and Louisiana. Nineteen states 
have civil and/or criminal penalties for violation of genetic privacy laws.   Washington is 
the lone state that treats genetic information the same as other health information.  A 
complete table of each state’s discrimination laws regarding genetic and health insurance 
discrimination laws and states’ genetic employment laws is located at the National 
Conference of State Legislature website (http://www.ncsl.org/default.aspx?tabid=14287) 
(National Conference of State Legislatures, 2008). 
Who Does GINA Affect? 
It is impossible to say how many Americans are affected by genetic 
discrimination. A literature search using CINAHL, Academic Search Premier, Medline 
and other search engines for this data located no statistics. However the literature states 
that those Americans who fight discriminatory practices and win often have to invest 
significant time, money and effort to assert their rights (National Partnership for Women 
and Families [NPWF], 2008).  Unfortunately, not every afflicted individual will have the 
knowledge of discriminatory practices and/or resources available to assert these rights.  
Some will find themselves uninsured or unemployed because of their genetically induced 
risk for disease and associated healthcare related costs (NPWF, 2008).   
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Legislative History of GINA 
Representative Louise Slaughter (D-NY), a microbiologist, first introduced 
legislation to address genetic discrimination in 1995 during the 104th Congress (NHGRI, 
2009).  In 1996, Senator Olympia Snowe (R-ME) introduced similar legislation in the 
Senate.  Both bills addressed health insurance discrimination, however neither bill 
passed.  Similar legislation was introduced in both Congressional chambers in the next 
four successive Congresses. In the 109th Congress, Representative Judy Biggert (R-IL) 
introduced the bill in the House of Representatives (H.R), and although it again passed in 
the Senate under Senator Stowe’s efforts, GINA still did not pass the H.R.  During the 
110th Congress, after passing through the three jurisdiction committees of Education and 
Labor, Energy and Commerce, and Ways and Means, GINA passed through both 
chambers of Congress, the Senate on April 24, 2008 and the House on May 1, 2008.  
With the perseverance of Representatives Slaughter and Biggert and Senator Snowe, a 
bipartisan Congressional effort and a strong coalition of interested organizations, GINA 
was “born” after a gestation period of 13 years in the United States Congress (Couzin, 
2008; CGF, 2008) (Figure 2.1).  Although GINA is not a perfect nondiscrimination law, 
it is an example of how legislative advocacy and a coalition of organizations effectively 
fought for a common cause.  The result was a more comprehensive genetic 
nondiscrimination law on a federal level, rather than having fifty different individual state 
nondiscrimination laws. 
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Figure 2.1 
GINA Legislative History 
Based on “What does GINA Mean?  Guide to the Genetic Information Nondiscrimination 
Act” (2008) Coalition for Genetic Fairness (www.geneticfairness.org.)  and “Major 
Events in the Human Genome Project and Related Projects” (2009) Human Genome 
Project Information (www.ornl.gov/sci/techresources/Human_Genome/ 
project/timeline.shtml). 
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The Genetic Information Nondiscrimination Act (GINA), also known as Public 
Law 110-233, was signed into law by President George. W. Bush on May 21, 2008.  The 
late Senator Ted Kennedy (D-Mass.) applauded GINA as ‘the first civil rights bill of the 
new century of the life sciences”.  This law makes it illegal for health insurers or 
employers to discriminate against individuals based on their genetic information.  The 
health insurance provisions of the bill, Title I, took effect 12 months after the signing date 
on May 21, 2009.  The protections in employment, Title II, took effect 18 months after 
the signing date on November 21, 2009 (CGF, 2008).  Title II applies to private 
employers, local and state governments with 15 or more employees.  It also applies to 
labor unions, employment agencies, labor-management programs, Congress and federal 
executive agencies (The U.S. Equal Employment Opportunity Commission, 2009).    
GINA is not a perfect genetic discrimination bill, there are still loopholes.  The 
goal of comprehensive genetic nondiscrimination is difficult with a health finance system 
where individual health insurance is medically underwritten.  Current employment laws 
do not protect the complete privacy of employees’ health information and GINA’s 
provisions do not apply to life, long-term-care and disability insurance. 
Proponents and Opponents 
GINA had many “official actors” in the federal legislature and thousands of 
“unofficial actors”, who were personally concerned about their own future or realized 
genetic discrimination. In 1997, when genetic discrimination bills did not pass the 106th 
Congress, the largest organized “unofficial actor”, the Coalition for Genetic Fairness 
(CGF) was formed.  CGF includes a number of diverse organizations, including Alpha-1 
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Association, Genetic Alliance, Hadassah, National Partnership for Women and Families, 
National Society of Genetic Counselors and the National Workrights Institute.   CGF’s 
objective is to educate the public and Congress about genetic discrimination, so that 
introduced genetic nondiscrimination legislation can be seriously considered. Since its 
founding, the CGF has united hundreds of organizations and thousands of individuals as 
one voice against genetic discrimination (CGF, 2008).  These organizations recognize 
that their mutual goal among diverse groups is to accomplish passing genetic 
nondiscrimination legislation; a goal out of reach for any one of the organizations (CGF, 
2008).  
In 2005, the CGF expanded to include industry and employers.  Once these 
groups were educated about GINA, they supported its proposed legislation.  Besides a 
majority of legislators and the CGF, GINA was supported by more than 500 
organizations, medical groups, individuals and companies, including the American 
Medical Association, the American Nurses Association, the National Education 
Association and the March of Dimes (Lengell, 2008).   
GINA legislation was opposed by insurance companies and the Genetic 
Information Non-Discrimination in Employment Coalition (GINE), made up of the 
National Association of Manufacturers, the National Retail Association and others.  This 
coalition included the United States Chamber of Commerce (U.S. C. of C.) who argued 
that the bill‘s language was too broad, did not support many state laws and provided for 
severe punitive damages.  Opponents also claimed worried plaintiffs would turn 
common, ordinary disputes over insurance coverage into full-blown civil-rights cases 
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(United States Chamber of Commerce, 2007). The U. S. C. of C.’s executive director for 
labor policy stated disappointment with current provisions of GINA, noting other 
concerns of the U.S.C. of C. were not addressed before the bill was passed (Board of 
National Affairs, 2008).   
GINA’s Provisions 
Genetic information is information about an individual or family members’ 
genetic tests, the occurrence of disease in family members or the individual and/or 
participation of a family member in research that includes genetic testing, counseling or 
education (Rothstein, 2008;  GPPC, 2008). Genetic information does not include 
information about the sex or age of an individual.  A genetic test refers to a test that 
assesses genotypes, mutations, polymorphisms and/or any chromosomal changes in an 
individual (GPPC, 2008).  There are four main concerns, regarding use of genetic 
information in employment and health insurance which drove efforts to obtain genetic 
nondiscrimination legislation.  These same concerns could also be applied in future 
campaigns regarding use of genetic information in life, disability and long-term care 
insurance (Rothstein, 2008). 
The first concern focused on individuals worrying about having pieces of their 
health records combed through by insurance companies probing for any evidence of 
genetic information (Rothstein, 2008).  For example, a patient, who had multiple family 
members in multiple generations with breast and ovarian cancer, should be concerned 
about having this information identified when the insurance company was requesting 
documentation of medical necessity for a gall bladder “attack”.  Because the physician’s 
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office staff was so busy, the entire patient chart was faxed to the insurance company 
instead of only necessary pieces of medical chart information.  
The second fear was genetic testing could be required as a provision of 
employment.  Once the results are received, the patient finds out information about 
personal health risks they did not want to know.  Third was the worry that a future 
employer or health insurance underwriter would misinterpret a person’s genetic 
information, using it to disqualify them for a job or insurance coverage (Rothstein, 2008).  
Oncology professionals know a genetic mutation in a gene does not mean an individual 
will develop cancer.  The possibility of developing a cancer does not mean an individual 
could not perform a job for which they are qualified, and should not disqualify them for 
insurance. Finally was the fear that inquiring about and having a genetic test would 
exclude them from insurance benefits available to those who have never had any genetic 
testing.  Individual were concerned that even with negative results would prevent them 
from obtaining adequate insurance (Rothstein, 2008). 
GINA addresses the above concerns by prohibiting use of an individual’s genetic 
information to set eligibility on premiums or contribution amounts for group and 
individual health insurers.  Health insurers are prohibited by GINA from requesting or 
requiring an individual to take any genetic test.  However, a health insurer or group 
health plan involved in research may request, but not require a genetic test, in conjunction 
with specific research activities.  The research must comply with Federal regulations 
regarding protections of human subject and must notify the Federal government in 
writing that it is conducting research.  Of note, oncology patients (beneficiary or legal 
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guardian) participating in clinical trials should receive written requests for voluntary 
genetic testing should be made in writing to the participant, beneficiary or legal guardian, 
with the clear statement that research genetic testing would have no effect of eligibility 
for benefits and would not affect premiums (United States Department of Labor [U.S. 
DOL], 2009)  
Employers are also prohibited in the use of an individual’s genetic information, 
(family history, genetic testing, counseling or education, and participation in any clinical 
research), in any employment decision such as hiring, firing, job assignments or 
promotions.  Finally, GINA prohibits employers from requesting, requiring, or 
purchasing genetic information about an individual’s family members (up to and 
including 4th degree relatives), as well as genetic tests of any fetus of a pregnant family 
member or legally held embryo from assisted reproductive technology of an individual 
(Rothstein, 2008).  
What GINA does not do is prohibit medical underwriting based on an individual’s 
current health status; someone diagnosed with breast cancer after genetic testing 
identified a BRCA mutation may still have their insurance cancelled due to the disease 
but not the genetic testing.  It does not mandate insurance coverage for any specific 
medical test or treatment.  GINA does not interfere with a health care professional 
requesting that an individual or family member undergo a genetic test.  It does not limit a 
health care professional, who may be employed by a health plan or insurance company, 
from notifying an individual about diagnostic or predictive genetic tests or providing 
information to an individual about a genetic test as part of a wellness program.  It does 
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not subject employers to rules and regulations that are any different from other civil 
rights laws.  Workplace collection of genetic information for toxic monitoring programs, 
employer-sponsored wellness programs, administration of federal and state Family and 
Medical Leave laws, and certain cases of unintended acquisition of genetic information is 
not prohibited.  However the employer may not use or disclose the genetic information 
for any purpose (GPPC, 2008).  GINA does not include protection from genetic 
discrimination in life insurance, disability insurance or long-term care insurance.    
GINA’s provisions do not apply to members of the United States Military, to veterans 
obtaining health services through the Veteran’s Administration, or care through the 
Indian Health Service (GPPC, 2008) (Table 2.1). 
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Table 2.1 
Provisions and Limitations of GINA 
Provision Not Included 
Prohibits use of an individual’s genetic 
information in setting eligibility or premium 
amounts by group and individual health insurers. 
Does not prohibit medical underwriting based on 
current health status or mandate coverage for any 
particular medical test or treatment. 
Prohibits health insurers from requesting or 
requiring an individual to take a genetic test. 
Does not interfere with ability of a health care 
professional to request an individual or family 
undergo genetic testing. 
Prohibits use of an individual’s genetic 
information by employers in employment 
decisions such as hiring, firing, job assignments, 
and promotions. 
Does not limit health care professional, employed 
by a health plan, from notifying an individual 
about genetic tests or providing information about 
a genetic test as part of a wellness program. 
Prohibits employers from requesting, requiring, or 
purchasing genetic information about an 
individual employee or family member. 
Does not: 
 Subject employers to remedies and 
procedures different from civil rights laws 
such as Title VII and the Americans with 
Disabilities Act. 
 Prohibit workplace collection of genetic 
information for toxic monitoring programs, 
employer-sponsored wellness programs, and 
administration of federal and state Family 
and Medical Leave laws. 
 Include protection from genetic 
discrimination in disability or long-term care 
insurance. 
This law went into effect for health insurers on 
May 21, 2009.The law in regards to employment 
genetic discrimination went into effect in 
November 2009. 
Does not apply to members of the military, 
Veteran’s Administration, or the Indian Health 
Service. 
Adapted with permission from “A Discussion Guide for Clinicians”, Genetic and Public 
Policy Center, Johns Hopkins University, www.dnapolicy.org/resources/GINAfinal-
discussionguide-3June10.pdf. 
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Changes to Existing Federal Laws 
One existing law impacted by GINA is the Employee Retirement Income Security 
Act (ERISA).  Amendments include provisions that prohibit group health insurance 
issuers from denying coverage or discriminating in premium pricing or policy due to an 
individual’s genetic information.  GINA also prohibits these issuers from requesting or 
requiring a pre- or post-enrollment individual to have genetic testing and prohibits the 
insurers from accessing the genetic information by request, requirement or the purchase 
of their genetic information.  This means person with a family history of inherited 
cancers, like breast and ovarian, cannot be required by their insurance companies to have 
genetic testing.  In addition, the insurance company cannot request, require, or purchase 
the results of genetic tests.   
Amendments to the Public Health Service Act (PHSA) include prohibiting health 
insurance companies from offering coverage to individuals based on their genetic 
information.  GINA prevents these insurance companies from excluding coverage of 
preexisting conditions based on genetic information. GINA states that genetic 
information should be treated as health information under (Health Information Portability 
and Accountability Act (HIPAA).  This means genetic test results, a pedigree indicating 
an inherited cancer syndrome, or family history of cancer cannot be the only reason to 
deny insurance coverage.  In addition, patients cannot be denied coverage for a 
“preexisting condition”, based on genetic test results showing positive for a mutation 
(GPPC, 2008).   GINA also prohibits using genetic information for Medicare purposes 
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and to issuers of Medigap policies, amending both the Internal Revenue Code and Social 
Security Act (Laurent, Klamath & Sullivan, 2008; U. S. DOL, 2009) (Table 2.2). 
GINA’s health insurance provision does not apply to three groups of Americans.  
Prior to genetic testing, oncology nurses need to carefully determine if their patients or 
family are planning to receive or are receiving health care through the United States 
Military, Veteran’s Administration, or Indian Health Service (GPPC, 2008).   
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Table 2.2 
Changes to Existing Federal Laws 
Law Change 
Employee Retirement Income Security 
Act 
(ERISA) 
Prohibits group health insurers from denying coverage or 
discrimination in price policy or premium change due to 
individual’s genetic information. 
Public Health Service Act (PHSA) Prohibits health insurers from offering individual coverage 
based on genetic information. 
Health Information Portability and 
Accountability Act (HIPAA) 
Genetic information should be treated as health information. 
Internal Revenue Code of 1986 
Social Security Act of 1965 
Prohibits use of genetic information in regards to Medicare 
and Medigap coverage. 
Based on “Genetic Information Nondiscrimination Act of 2008” by D. Laurent, J 
Klamath, & C .Sullivan, 2008 
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Enforcement of GINA 
GINA’s health provisions are enforced through agencies whose laws were 
amended, thus affected, by GINA.  The Departments of Labor, Treasury and Health and 
Human Services enforce Title I of GINA and the Equal Employment Opportunity 
Commission (EEOC) is responsible for the enforcement of Title II (NHGRI, 2009). The 
privacy provisions in Title II of GINA enforced through HIPAA, include civil fines of 
$100/violation incidence and criminal fines to $250,000 with 10 years in prison for 
violations of a commercial and malicious nature (Laurent, Klamath & Sullivan, 2008),   
Also in Title II is the provision that individuals have the right to pursue private litigation 
(NHGRI, 2009).   ERISA and PHSA enforce discrimination provisions with fines of 
$100/day/person, ranging from $2,500 to $15,000 with a maximum of $500,000 for 
unintentional discrimination violations.  Penalties for violations of discrimination due to 
reasonable cause or neglect are authorized by The Secretary of Labor (Laurent, Klamath 
& Sullivan, 2008). 
Examples of protected genetic tests under GINA are the mutations associated with 
Hereditary Breast and Ovarian Cancer and hereditary nonpolyposis colorectal cancer 
(HNPCC), genetic properties of an existing tumor that could to help determine therapy, 
Huntington’s Disease mutation and carrier screening for disorders, such as cystic fibrosis, 
sickle cell anemia, spinal muscular atrophy and Fragile X syndrome. Routine tests such 
as complete blood counts, cholesterol and liver-function tests are not protected under 
GINA.  Also not protected under GINA is DNA analysis of infectious agents such as 
bacteria, viruses, and fungi. Following this reasoning, an HIV test is not covered under 
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GINA, since HIV is not human DNA, rather a retrovirus that inserts itself into human 
(GPPC, 2008). Under GINA, a genetic test is also not an analysis of proteins or 
metabolites that relate directly to a disease or pathology that could be detected by a health 
care professional on an annual exam or follow-up appointment (NHGRI,2009) (Table 
2.3).   
 32 
Table 2.3 
Protected and Non-protected Genetic Tests in GINA 
Protected Genetics Tests Non-protected Genetic Tests 
Examples:  Genetic tests for Hereditary Breast and 
Ovarian Cancer, Hereditary Nonpolyposis 
Colorectal Cancer, Huntington’s Disease, etc. 
Routine tests – Complete blood counts, blood 
chemistries, cholesterol and liver function tests.  
Analysis of proteins or metabolites relating 
directly to a disorder or disease. 
Carrier screening tests such as those for cystic 
fibrosis, sickle cell anemia, spinal muscular 
atrophy and Fragile X syndrome 
Infectious agent tests for bacteria, virus (including 
HIV), and fungi. 
* The term “genetic tests” refers to the analysis of human DNA, RNA, chromosomes, 
proteins, or metabolites that detect mutation, changes to chromosomes and genotypes. 
 
Based on “GINA”, National Human Genome Research Institute (2009), 
www.genome.gov/Pages/PolicyEthics/.../GINAInfoDoc.pdf.html. 
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Despite a comprehensive prohibition on employer acquisition of genetic 
information, it is very likely that employers would continue to obtain genetic information 
due to conversations (water-cooler talk) and inadvertently through serendipitous 
discovery when searching for results to common laboratory tests.  In accordance with 
section 102(d)(3) of the Americans with Disability Act ( ADA), after a conditional offer 
of employment, employers are permitted to require, as a condition of employment, that 
individuals submit to a medical examination and sign an authorization for the release of 
their health records. According to Rothstein (2008), each year in the United States, 
potential employees sign an estimated 10.2 million authorizations for release of their 
health records.  Because of the increased networking of electronic medical records, the 
disclosure of health records is becoming extensive.  Even if employers requested only 
nongenetic records, there’s no assurance this would be done.  Since it is time-consuming 
to search for, identify and pull out of the chart specific information to send in response to 
requests, it is easier to send the whole record. Perhaps the persons sending the complete 
medical records are unaware and not appreciative of GINA’s provisions.  A current 
concern of individuals is that employers could have inadvertent access to genetic test 
results.  This still remains a major issue for many individuals when GINA is enacted.  
Complete protection of genetic information requires banning employer requests for 
comprehensive records at the pre-employment and other stages of employment, annual 
check-ups or wellness programs. Health information technology needs to research, adopt 
and ensure the disclosure of only job-related health information with legal ramifications 
for disclosure of genetic information to be adopted (Rothstein, 2008). 
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The Future of GINA 
Since GINA was signed by President George W. Bush in 2008, federal 
bureaucratic agencies began implementing GINA under a new administration in 2009. 
Will GINA change as the “players” or “official actors” in the federal government 
changed?  The proposed Obama health care plan addresses the problem of genetic 
discrimination in two ways.  First, it prohibits private insurance companies from 
excluding individuals from coverage based on pre-existing health conditions, something 
GINA does not presently provide.  Secondly, if insurance companies cannot exclude 
individuals based on preexisting conditions, then claims cannot be denied payment based 
on those preexisting conditions (Obama/Biden Plan, 2009).    
Enactment of GINA declared a national policy against discrimination in health 
insurance and employment based on genetic information.  However, GINA still has many 
associated risks. First, GINA could increase the stigma associated with genetic conditions 
by treating the genetic information separately and differently from other health 
information.  Second, individuals convinced of GINA’s value may undergo predictive 
genetic testing and inadvertently have their test results leaked to present or future 
employers.  Finally, only time will tell if GINA’s protections adequately address the 
issues of genetic discrimination in employment and health insurance. 
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Abstract 
All nurses have the responsibility to deliver nondiscriminatory genetic healthcare.  
Patients perceive discriminatory nursing practices when they are being treated differently 
and unfairly.  Nurses are expected to integrate genetic information about their patients 
into their clinical decision making.  Thus it is both timely and imperative that nurses have 
an operational definition of the concept, “awareness of discrimination based on genetic 
information.” 
An operational definition of the concept was derived and Wilson’s method of 
concept analysis was utilized to show how the operational definition may be applied in 
three different case models. Awareness of discrimination based on genetic information 
can be operationally defined as “to know differences against people or distinguish 
between people based on the ancestral, heritable, communicated facts or knowledge”. 
This concept analysis of words and terms used in genetic health care may serve as 
a framework for further genetic/genomics healthcare concepts under exploration. 
Introduction 
In the first decade of the 21st century, two major events have changed the 
paradigm of health and well-being for United States (U.S.) citizens.  The first event to 
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occur was the completion of the Human Genome Project in 2003.  This event established 
a new conceptualization of healthcare services, by adding genetic consideration to 
incidence, etiology, diagnosis, and treatment of many common diseases, such as 
cardiovascular disease and many types of cancer (ISONG).  The second event was 
signing the Genetic Information Nondiscrimination Act (GINA) of 2008 into law, 
providing federal protections to U.S. citizens, by outlawing discrimination based on 
genetic information when seeking health insurance and employment (Rothstein, 2008). 
In response to these events, the Code of Ethics for Nurses, developed by the 
International Council of Nurses and the American Nurses Association, now states that all 
nurses have the responsibility to deliver nondiscriminatory genetic healthcare.  
Additionally, the International Society of Nurses in Genetics (ISONG) has issued a 
position statement declaring that professional nurses should be aware of laws pertaining 
to genetic information and also become aware of potential discrimination linking genetic 
information with race, gender, ethnicity and other social constructs (Access to Genomic 
Healthcare, 2010; Privacy and Confidentiality of Genetic Information, 2010). 
Discrimination exists within the nursing profession.  Numerous research studies 
have shown that nurses discriminate against their patients and also within the nursing 
profession in eight broad categories:  race, religion, gender, social class, lifestyle 
behaviors, nationality, physical disability and political beliefs.  Nurses have also been 
shown to discriminate against patients based on their health status; whether they are 
human immunodeficiency virus positive, overweight or possess a mental illness 
(Thornburn Bird, Bogar & Delahanty, 2004; Hocking, 2003; Puhl & Brownell, 2001).   
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Patients perceive discriminatory nursing practices when they are being treated differently 
and unfairly. However, such discriminatory practices are difficult to prove since they are 
often implicit, indirect and subtle (Kingma, 1999; Klitzman, 2010).  When and if nurses 
become aware of these discriminatory practices toward patients’ status, in particular 
patients’ genetic healthcare status, they can then take appropriate actions towards 
reducing these painful and often harmful practices (Kingma, 1999; Lea, 2008). 
Because the nursing profession is essential to the delivery of nondiscriminatory 
genetic healthcare, nurses will be expected to integrate genetic information about 
individuals into their clinical decision making (Williams, 2002; Lea, 2008). Thus, it is 
both timely and imperative that nurses today have an operational definition and essence 
of the concept, “awareness of discrimination based on genetic information”, the concept 
this paper will explore.  
 “Awareness” may be considered a special form of awareness, reflexive 
awareness. Consciousness has a more restricted meaning, from the Latin words ‘cum’ 
and ‘sciere’ translated “to know about”.  Consciousness in humans may be considered an 
experience also, like awareness’ experience, but is an experience that is evoked by 
thinking “about” one’s experience, to distance oneself from the current awareness 
experience, as if to observe it in third person (Vaneechoute, 2000).        
Background 
Because the concept, “awareness of discrimination based on genetic information” 
is not currently found as an entry in dictionaries, the individual words, “awareness, 
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discrimination, genetic and information” and the term “genetic information” will be 
analyzed and then synthesized into an operational definition. 
Awareness is defined in The Oxford English Dictionary (OED, 2010) as” the 
quality or state of being aware; consciousness”. By introspection you experience what 
you have been experiencing in the world, including internal and external objects (The 
Cambridge Dictionary of Philosophy, 1995). “Aware” derives from the Anglo Saxon 
word “gewaer”, first used in the 11th century, meaning “being informed”.  From the 13th 
century to present day, awareness is also synonymous with “to know” relating to 
experiences: the act of experiencing (Vaneechoute, 2000).   
Awareness and consciousness have also been used as synonyms, though 
consciousness may be considered a special form of awareness, reflexive awareness. 
Consciousness has a more restricted meaning, from the Latin words ‘cum’ and ‘sciere’ 
translated “to know about”.  Consciousness in humans may be considered an experience 
also, like awareness’ experience, but is an experience that is evoked by thinking “about” 
one’s experience, to distance oneself from the current awareness experience, as if to 
observe it in third person (Vaneechoute, 2000).        
Discrimination, derived from the Latin word, ‘discrination-em’, translates to “of 
action”, can be defined as the action of perceiving, noting or making a difference or 
distinction between things, made with the mind or in action.  Specifically, discrimination 
has been used to describe an act of distinguishing against people based on race, color, 
sex, or social status (OED, 2010). A synonym for discrimination is “against”. 
Discrimination frequently is defined in legal literature as an action, based on real or 
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perceived differences from a certain standard, unfavorable to the person who deviates 
from that standard (Spaak, 2006). 
Genetic refers to the basic units of heredity, genes (Williams, Skirton, & Masny, 
2006).  Used as an adjective, it is defined as relating to common an evolutionary or 
ancestry origin. Information is defined as knowledge communicated concerning some 
particular event or fact, it can be synonymous with intelligence or news (OED, 2010). 
Currently, the term, genetic information, is not found as an entry in dictionaries. Genetic 
information is defined mainly in a legislative sense. GINA defines genetic information as, 
‘information about an individual’s genetic test and the genetic tests of an individual’s 
family members, as well as information about any disease, disorder, or condition of an 
individual’s family members (i.e. an individual’s family medical history up to a 4th 
degree relative).  A genetic test is defined by GINA as an analysis of human DNA, RNA, 
chromosomes, proteins, or metabolites that detect genotypes, mutations or chromosomal 
changes (GINA, 2010; Rothstein, 2008).    Genetic information is heritable, biological 
information; it can be identified at any point throughout a person’s lifespan from pre-
conception until after death (Lea, 2008). Genetic information is considered to be different 
from other health information, due to the unique quality of genetic information that 
identifies an individual, the stability of the DNA to be stored indefinitely and the ability 
of DNA to generalize specific genetic information to families, genetically-related 
communities, as well as ethnic and racial populations (Spaak, 2006). A descriptive 
definition of the phrase, “discrimination based on genetic information” has been applied 
to date in the legal arena to individuals who experience the denial of rights, privileges, or 
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opportunities based solely on genetic information, the term is not applied to individuals 
who have developed symptoms of a genetic disease (Erwin et.al, 2010). 
Operational Definition 
After studying the definitions, uses and attributes of the individual words and 
term used in the concept under exploration, an operational definition for “awareness of 
discrimination based on genetic information” can be derived.  Awareness of 
discrimination based on genetic information can be considered as “to know differences 
against people or distinguish between people based on their ancestral, heritable, 
communicated facts or knowledge.” 
Concept Analysis Method 
Wilson’s method of concept analysis is appropriate to analyze the concept being 
explored, since awareness of discrimination based on genetic information has not been 
previously explored using concept analysis.   This method incorporates an introductory, 
simple, flexible, yet thorough way of dissecting and restructuring a new concept, with the 
goal of understanding the concept and its application.  Wilson’s method begins by 
isolating the concept for analysis, first examining situations from literature where the 
concept is used. Wilson recommended using actual cases or developing cases designed to 
highlight the differences the concept under analysis makes to a situation or event. 
Invented cases are only constructed when there are not enough actual cases available to 
illustrate the concept. Epistemically, these cases formulate evidence of the concept under 
review. This evidence is then used to help justify a belief or theory (Hupcey, Morse, Lenz 
& Tason, 1996; Risjord, 2009). 
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Utilizing a nursing theory as framework is fundamental to new nursing 
knowledge development.  The Roy Adaptation Model’s broad nature allows examination 
of awareness of discrimination based on genetic information from an expanded holistic 
nursing perspective.  The individual at risk for developing genetic disease is viewed as a 
thinking and feeling individual with interrelated parts that comprise a unified whole.  An 
individual with an imperfect genetic make-up can be viewed as an adaptive system, using 
coping processes that act to maintain adaptation to the physiological and self-concept 
modes (Hannon-Engel, 2008).  The concept of awareness of discrimination based on 
genetic information can add evidence to Roy’s scientific assumption that awareness of 
self is rooted in thinking and feeling, that helps mediate human action (Phillips, 2010, p. 
341). 
Methodology 
Search strategy for this concept analysis, included articles written in English, 
published from 1995-2010. Limiters were full text, references available and peer 
reviewed journals. The starting year of 1995 was chosen to retrieve published articles that 
regarded discrimination based on genetic information, since questions about how results 
of the Human Genome Project (1990-2003) were being raised while the human genome 
was being sequenced.  Exclusion criteria used was that articles retrieved had to applicable 
to discrimination and genetic information definitions used in the United States.  Other 
countries such as the United Kingdom and Australia have their own specific genetic 
information nondiscrimination laws, using different definitions of genetic information. 
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Electronic databases used in the search were: Academic Search Premier, 
CINAHL Plus with Full Text, Cochrane Database of Systematic Reviews, ERIC, Health 
Source:  Nursing/Academic Edition, MEDLINE, PsycINFO, LexisNexis and OED for 
individual concept word definitions.  In addition, ProQuest Database, specifically 
Dissertations and Abstracts, was included in the search.  MeSH terms, Boolean operators 
and wild carding in several combinations used the terms aware*AND discriminat* AND 
gene* which yielded 111 abstracts.  However since awareness is the main concept under 
examination, “awareness” was put in the Title field (TI), OR discrimination AND genetic 
information was put in any field which yielded 2588 articles.  Awareness (TI) AND 
discrimination AND genetic information yielded zero articles.  So, awareness (TI) AND 
discrimination OR genetic information was used, yielding 427 articles, which, after being 
scanned for inclusion and exclusion criteria yielded 30 articles, in which a search for 
secondary sources was conducted.  In addition this author searched through articles 
previously used by the author to complete other papers, which yielded another 10 articles. 
Findings 
Wilson stated that in order for a concept analysis to be conducted, the concept 
question must be answered from factual, constructed or invented cases.  The concept 
question for the analysis then would be:  what constitutes awareness of discrimination 
based on genetic information?  The following cases are from real situations that have 
occurred. 
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Model Case 
Model cases help provide a clear example of a concept.  Mary is an example of 
individual awareness of discrimination based on genetic information.  Mary has a family 
history of breast cancer; both her mother and aunt have been diagnosed with the disease.  
Mary considers being tested for the BRCA-1 gene, hoping to take prophylactic measures 
to reduce her risk of developing breast cancer if the genetic test result was positive.  
Currently the BRCA-1 gene testing is only performed by Myriad Corporation, who holds 
that patent for that particular genetic test. She debates paying for the test herself, but as a 
recent law school graduate, she cannot afford it.  Mary decides not to undergo testing as 
she fears a positive test result would be reported by her company’s insurance carrier and 
could possibility jeopardize her changes for future promotion at her law firm (Faces of 
Discrimination, 2004). 
In this case, Mary is aware; she knows her family’s health history, a form of 
genetic information that can impel an individual to undergo further testing for a gene 
known to cause breast cancer.  Mary is also aware of the possibility of discrimination 
based on the genetic information obtained from the genetic testing, that would be 
reported back to her employer’s insurance company, affecting her ability to qualify for 
life, disability, and long-term care insurance when the claim for genetic testing is filed. 
Contrary Case 
Wilson also suggested including contrary cases which might clearly identify 
which cases do not meet the definition of the concept being analyzed.  An individual 
whose genetic information becomes known to other persons outside the healthcare arena 
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may unknowingly face discrimination.  For example, a single mother in Washington 
filled out her job application truthfully, acknowledging a family history of Huntington’s 
disease.  She was passed over, in her small company, for promotions and pay raises 
without explanation, despite being named employee of the year and receiving excellent 
performance evaluations.  This mother was discriminated against on the basis of her 
family’s health history, a form of genetic information.  She was not aware that her family 
history was a source of genetic information that could be used to discriminate against her.   
In this case, the risk of discrimination provides motivation for individuals, aware of their 
family health history, to keep their personal genetic information a secret.  Because DNA 
is essential to human life, it is seen as being the determinate to everything that human is 
or will become (Fedder, 2000). 
Borderline Case  
 A borderline case is an example that contains most of the concept’s elements, but 
not all of them.  The following cases help clarify defining attributes of the concept. One 
such case concerns a nurse working at an oncology clinic who encountered a young 
woman whose mother and sister died of breast cancer.  The young woman refused to sign 
in at the front office.  The nurse explain that registration was required and that the 
woman’s genetic information would be kept entirely confidential  The women then 
became extremely emotional, saying she believed she would expose herself and her child 
to discrimination if her visit to the clinic was documented.  The nurse tried to encourage 
the woman to stay, but she left the office without testing or counseling and without 
scheduling an oncology screening (Faces of Discrimination, 2004).   
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 The other borderline case involves Gail, a physician with a family history of 
breast and ovarian cancer, who faced potential discrimination because of her incomplete 
medical records.  Gail decided to take a genetic test to determine her risk for breast and 
ovarian cancer.  In order to avoid discrimination regarding her insurability, she took the 
test under an assumed name and purposely kept her family history information out of her 
medical record.  Before Gail received her genetic test results, Gail’s gynecologist noticed 
a possible abnormality on her ultrasound during a routine visit.  As Gail’s risk factors for 
cancer and her genetic test were not noted on her medical chart, her doctor was unaware 
of a possible hereditary risk and did not recommend follow-up testing nor a course of 
treatment.  Since Gail was a physician, she was aware of the significance of her exam 
results and knew what she needed to do to protect herself.   However for individuals not 
in a healthcare profession, this case could result in a patient’s lost opportunity for follow-
up resulting from a missed detection of a life-threatening disease. 
 In these borderline cases, some attributes of the concept are missing.  In the first 
case, it is the oncology nurse who is not aware of possible discrimination the young 
woman and her children could face if she registered at the clinic and underwent genetic 
screening.  The young woman was not aware that registering in at the clinic is not 
considered genetic information.  Gail, the physician, although aware of possible 
discrimination based on genetic information, is not aware that by undergoing anonymous 
genetic testing, with results not revealed to her gynecologist, she could face 
discrimination and new health risks by not qualifying for follow-up treatment, based on 
keeping her genetic information secret (Faces of Discrimination, 2004). 
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 These cases illustrate that, in order to be aware of discrimination based on genetic 
information, all elements of the concept must be present.  Patients and healthcare 
professionals need to know how differences in individuals based on their family health 
history and genetic tests can be used to discriminate against them, either in the healthcare 
arena by not getting the appropriate treatment, or in the insurance or employment sectors. 
 Although most of these cases were reported before GINA was enacted, they are 
still applicable to this concept analysis, as most healthcare professionals and the public 
are not aware that GINA protects against health insurance and employment 
discrimination.  However, GINA does not protect individuals from being discriminated 
against when qualifying for life, disability, and long-term care insurance.  In addition, 
employment discrimination does not apply to employers who have less than 15 
employees (GINA, 2010; Rothstein, 2008). 
Limitations 
 A limitation of this analysis is that the data search and concept analysis was 
completed by one individual from only one perspective.  But, as awareness of 
discrimination based on genetic information is a new unexplored concept, this single 
perspective can serve as a launching point for other concept analyses, using different 
concept analysis methods to expand on and to incorporate descriptions of the concept in 
subsequent nursing research and discussions (Bonis, 2008). 
 An additional limitation is that most cases and the definition of discrimination and 
genetic information are taken from legal aspect.  As genetic consideration for illness and 
knowledge of GINA becomes commonplace in healthcare settings, cases of 
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discrimination based on genetic information may be researched and reported from a 
healthcare aspect. 
Future Development of the Concept 
 Future concept analyses expanding on this concept could include self-awareness, 
integrated awareness, reflexive awareness or situational awareness of discrimination 
based on genetic information.  In addition, instead of using awareness as an element of 
the concept which is “to know”, as U.S. citizens become aware of GINA’s provisions and 
limitations, the term consciousness, “to know about” could add further insight into this 
concept. Also, further nursing research is warranted to improve awareness in the 
healthcare arena, understanding the causes, and health consequences of discrimination 
based on genetic information (Thorburn Bird, 2004). 
Conclusion 
 This concept analysis serves as a starting point for future concept analysis of 
words and terms used in genetic healthcare.  As most common illnesses have a single or 
multiple genetic commonalities, nurses need to incorporate issues concerning genetics 
when providing patient care.  Roy’s Adaptation Model is an appropriate framework to 
guide this concept analysis, but other nursing theories and models may also guide further 
genetic-related concept analyses. Using Roy’s Adaptation Model, the cases presented in 
this analysis provide addition content to the model, representing real examples of how 
genetic information, only a part of our whole self, can affect an individual’s health 
holistically. 
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 As genetic research expands and preventive and treatment strategies for genetic 
diseases are developed, it will be increasingly important that discrimination and/or the 
fear of discrimination not be a roadblock to reaping the benefits (Clifton, VanBeuge, 
Mladenka & Wosnik, 2010). Genetic information will continue to change with each new 
genetic discovery.  The nursing discipline needs to develop knowledge to guide genetic 
nursing practice for all individuals in all healthcare settings (Williams, 2002).  As health 
professionals, nurses have a responsibility to put their own house in order first, to 
increase the awareness and knowledge of discrimination based on genetic information 
(Hocking, 2003). 
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CHAPTER FOUR 
 
ASSESSING AWARENESS OF THE GENETIC INFORMATION  
 
NONDISCRIMINATION ACT OF 2008 (GINA) AMONG NURSE 
  
PRACTITIONERS:  A PILOT STUDY 
 
(To be submitted to the Journal of the American Association of Nurse Practitioners) 
 
Abstract 
Purpose 
To assess the awareness of the Genetic Information Nondiscrimination Act of 
2008 (GINA) among nurse practitioners (NPs) in South Carolina.  
Methodology 
A cross-sectional descriptive pilot research study, using 65 NP volunteers from 
two nurse practitioner association in South Carolina used a web-based questionnaire, 
based on Rogers’ Diffusion of Innovations theory, to assess the awareness of GINA 
among NPs, the independent variable, with dependent variables of the NP volunteer: 
terminal academic degree, specialized clinical practice setting, years of clinical practice, 
age and adopter category and types of communication channels used to find clinical 
practice information. 
Conclusions 
Only 34% (N=22) of NPs volunteering for the study were aware of GINA. Fisher 
exact and chi square statistics found that awareness of GINA in NPs was not related to 
the NP’s terminal academic nursing degrees, the NPs’ clinical specialties where germline 
genetic testing is common versus uncommon, the years of the NPs’ clinical practice or 
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the age of the NPs. . Additionally, awareness of GINA in NPs was not associated with 
any of the adopter categories of the NP: an innovator, an early adopter, in the early or late 
majority of adopters or a traditionalist/laggard. NPs who were aware of GINA scored in 
the early adopter, early majority and late majority categories.  The communication 
channels that NPs used to gain clinical information also did not statistically indicate a 
relationship between awareness of GINA and the type of communication channels used 
by the NP participants.  Effect size analysis did show that NPs who are aware and not 
aware of GINA use similar communication channels to gain information.  This 
information can be used to effectively diffuse information about GINA using these 
communication channels.  Further investigation into awareness of GINA in NPs, 
including antecedent, innovation, and adoption factors that contribute to the awareness of 
GINA among NPs is warranted.  Additionally, further research with a different, larger 
sample of NPs in South Carolina may indicate statistically significant results between 
awareness of GINA and the study variables. 
Implications for Practice 
Advanced practice nurses may have witnessed discrimination, against their 
patients and families with pre-existing genetic diseases, from either health insurers or 
employers.  GINA offers protections from discrimination based on their genetic 
information to these individuals.  To protect their patients and their families, NPs should 
be aware of the provisions and limitations of GINA.  Education strategies to increase 
awareness of GINA could incorporate factors identified from Rogers’ Diffusion of 
Innovation theory to, not only meet the essential genetic and genomic competencies for 
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nurses with graduate degrees, but also to facilitate the diffusion and adoption of GINA by 
NPs.   
Background 
Genetic testing for highly penetrant disorders with clinical action ability is used to 
predict risk for future disease, to detect mutations associated with genetic conditions, and 
to guide treatment decisions (Genetics & Public Policy Center [GPPC], 2008, Green et al, 
2013).  Genetic test results may not only reveal genetic information to symptomatic and 
asymptomatic individuals, but it is possible that genetic test results may lead to 
discrimination by health insurers and employers (Chapman & Smith, 2002). Since the 
Genetic Information Nondiscrimination Act of 2008 (GINA)was enacted in 2009, health 
care professionals need to be aware of GINA’s provisions and limitations to assist their 
patients and families in making informed decisions regarding genetic testing 
(International Society of Nurses in Genetics (ISONG), 2010).  Recent legislation, the 
passage and enactment of the Patient Protection and Affordable Care Act (PPACA), does 
not amend GINA’s provisions and limitations, but rather serves the complementary 
purpose to guarantee health insurance for all individuals who request it, in particular, 
those patients with a pre-existing genetic condition (Sarata, DeBergh, & Staman, 2011; 
NHGRI, 2014). 
Advance practice registered nurses (APRNs) such as nurse practitioners (NPs), 
are well-positioned to integrate GINA’s protections into their clinical practice. APRNs 
conduct comprehensive health assessments, diagnose, and treat individuals and their 
families possessing actual or potential genetic health problems.  As facilitators/change 
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agents, APRNs transmit new knowledge to nurses at the bedside as well as to patients and 
their families (Doran, 2007).       
Historically, genetics and genomic content has not been routinely integrated into 
master’s level nursing education curricula.  Since GINA became enacted in 2009, 
genetics and genomic content, including didactic knowledge and skills, are required to be 
incorporated in graduate nursing curricula, so future APRNs will be stronger advocates 
for their clients and families possessing genetic disease risks (Consensus Panel on 
Genetics/Genomic Nursing Competencies, 2009).  NPs need to possess awareness and 
knowledge of GINA and its applicability to clinical nursing practice. Therefore, the 
purpose of this research study is to empirically assess the extent to which NPs possess 
this awareness and knowledge of GINA. 
A review of the literature supports the need for this research study.  Three 
unpublished master’s theses measured awareness of GINA among consumers, genetic 
counselors and primary care physicians (Fusina, 2009; Garrison, 2010; Pamarti, 2011) 
Two published articles and two abstracts of articles pending publication surveyed 
consumers and physicians about their awareness and attitudes about GINA (Allain, 
Friedman & Senter, 2012; Laedtke, O’Neill, Rubinstein & Vogel, 2011; Huang, Huston, 
& Perri, 2013; Qurehi, Warda, Rahaghi, Ferrer, Ramirez, Oliveria. . . Rahaghi, 2010).  
Table 4.1 describes the research studies conducted to study awareness and knowledge of 
GINA in consumers and healthcare personnel.  No studies were identified that utilized a 
theoretical framework to conduct their study.  More importantly, no study was identified 
that assessed awareness of GINA in the nursing profession. 
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Table 4.1 
Research Studies Assessing Awareness of GINA 
Author & 
Date 
Population Instrument/Method Study Purpose Findings 
Allain, 
Friedman,  
&  Senter 
2012 
1,699 members 
of a Hereditary 
Breast and 
Ovarian Cancer 
Syndrome 
advocacy group 
Anonymous online 
questionnaire, 34 items 
Examine awareness 
and attitudes about 
GINA 
45.7% were 
aware of 
GINA before 
taking the 
survey 
p< 0.0001 
Fusina  
2009 
56 physicians 
affiliated with  
Mount Sinai 
School of 
Medicine 
Anonymous online 
survey, 19 closed-ended 
questions and one open-
ended question 
Examine awareness of 
GINA by physicians 
42.9% were 
aware of 
GINA 
p=0.0004 
Garrison 
2010 
1,076 members 
of FORCE, 
(Facing Our Risk 
of Cancer 
Empowered) 
advocacy group 
and clients of 
Ohio State’s 
Clinical Cancer 
Genetics 
Program 
Anonymous online 
survey, 33 multiple-
choice questions 
Evaluate consumer 
knowledge and 
attitudes of GINA 
52.1 % of 
respondents 
were aware of 
GINA before 
the study 
p<0.02 
Laedtke, 
O’Neill, 
Rubinstein 
& Vogel 
2011 
401 members of 
American 
Academy of 
Family 
Physicians 
Mailed /online survey.  
Number of items on 
survey not reported 
Evaluate physician’s 
awareness/knowledge 
of GINA 
45.5% aware 
of GINA.  
10.3% self-
reported 
knowledge of 
GINA, 
p<0.001 
Huang, 
Huston, & 
Perri 
2013 
295 general 
population panel 
of U.S. citizens, 
ages 18-64 
17-item survey, included 
2 questions to measure 
awareness/knowledge of 
GINA 
Evaluate consumer 
awareness of genetic 
discrimination and 
GINA 
8.8% were 
aware of 
GINA, 3.4% 
knew GINA 
prohibits 
improper use 
of genetic 
information, 
p value not 
reported 
 61 
Pamarti 
2011 
257 genetic 
counselors from 
National Society 
of Genetic 
Counselors 
32- item online survey, 
adapted from previous 
surveys 
Assess knowledge 
about the scope of 
GINA and genetic 
discrimination in 
clients 
56% aware of 
general 
provisions of 
GINA, 99.3% 
knew about 
GINA’s health 
insurance 
protections 
p<0.05 
Qurehi, 
Warda, 
Rahaghi, 
Ferrer, 
Ramirez, 
Rahaghi 
2010 
41 physicians at 
Cleveland 
Clinic/Florida 
Questionnaire - number 
of items and type not 
reported 
Evaluate personal 
practice of ordering 
lab tests and 
awareness of GINA 
39% aware of 
protections 
offered by 
GINA.  99% 
wanted to find 
out more about 
GINA, 
p value not 
reported 
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Purpose of the Study 
The overall purpose of this pilot study was to assess the awareness of GINA 
among NPs. Research questions that guided this study are: 
1. Is there a relationship between terminal academic degrees (Master versus PhD 
and DNP) and awareness of GINA? 
2. Does awareness of GINA differ among NPs in clinical specialties where 
germline genetic testing is common versus those NPs in clinical specialties 
where germline genetic testing is uncommon? 
3. Is there a difference in awareness of GINA depending on years of NP clinical 
practice? 
4. Is there a difference in awareness of GINA depending on the age of the NP? 
5. Is there a relationship between awareness of GINA and the adopter category 
of the NP? 
6. What communication channels do NPs, who are aware of GINA, use to find 
information related to their clinical practice? 
Theoretical Framework 
Everett Rogers’ Diffusion of Innovations theory (DOI) guided this pilot study 
(Rogers, 2003). The DOI theory has been applied in education, public health, 
communication, economics and marketing disciplines. Most recently this theory was used 
as the framework to establish essential genetic and genomic nursing competencies for 
nurses seeking baccalaureate degrees (Consensus Panel on Genetic/Genomic Nursing 
Competencies, 2009; Jenkins & Calzone, 2007).   
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Rogers’ theory is based on diffusion, a special type of communication where 
messages that concern a new idea, or innovation, are conveyed between individuals.  
Diffusion of an innovation is defined as, “the process by which an innovation is 
communicated through certain channels over time among the members of a social 
system” (Rogers, 2003, p. 475). To diffuse an innovation, the potential adopter must first 
possess “awareness-knowledge” of the innovation; however, awareness alone does not 
lead to the adoption or rejection of the innovation.  Rogers’ identified five concepts; 
relative advantage, complexity, compatibility, trialability and observability of the 
innovation that may influence the rate of diffusion of the innovation.  Also, the time 
frame that an individual takes to adopt an innovation, as compared to time taken by other 
members in their social system, affects diffusion of the innovation.   
Five constructs were identified from the theory that may affect the diffusion of GINA 
among NPs.  These five constructs, included in Rogers’ definition of diffusion of an 
innovation, include:  
 Awareness-Knowledge 
 Innovation 
 Communication  
 Time 
 Social System                                             
 Constructs and their concepts, derived from the DOI theory, used in this study are 
summarized in Table 4.2. Constructs are identified in bold type with their unbolded 
concepts identified below the construct.  
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Table 4.2 
Constructs and Concepts Derived from DOI Theory 
Awareness-
Knowledge 
Innovation Communication Time Social System 
 Cognition 
 How-to 
knowledge 
 Principles 
knowledge 
 Relative 
Advantage 
 Complexity 
 Compatibility 
 Trialability 
 Observability 
 Mass media 
 Interpersonal 
 
 Innovators 
 Early adopters 
 Early majority 
 Late majority 
 Laggards/ 
Traditionalists 
 Demographics 
 Practice setting 
 Clinical specialty 
 Highest nursing 
degree attained 
 Year highest 
nursing degree 
attained 
 Genetic education 
included in most 
recent nursing 
curriculum 
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Methods 
Design and study sample 
This cross-sectional descriptive pilot research study employed a web-based 
questionnaire, using selected constructs and concepts from Rogers’ Diffusion of 
Innovation Theory that play roles in the awareness of GINA among nurse practitioners 
(NPs).  The independent variable used was “awareness” under the Awareness-Knowledge 
construct and the dependent variables were under the Social System construct: NP 
terminal academic degree, NP specialized clinical practice setting, years of NP clinical 
practice, age of the NP and adopter category of the NP as well as type of communication 
channels NPs use to find information related to their clinical practice. 
  According to a Kaiser Family Foundation report (2011), there are 3,687 licensed 
nurse practitioners in South Carolina.  E-mail addresses for NPs in South Carolina were 
unavailable from the SC State Board of Nursing and the SC American Nurses 
Association, so the memberships of nurse practitioner associations in South Carolina 
were used to obtain the convenience sample for this study. Eligible participants consisted 
of South Carolina licensed NPs from the NP memberships of two South Carolina nurse 
practitioner associations that responded to the researcher’s query for participants. The 
volunteer NP participants learned of the study by an e-mail communication from their 
association president a few days before receiving the email invitation which contained a 
link to the online questionnaire from the author.  
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Instruments 
To meet the overall purpose for this exploratory study, a new questionnaire was 
developed, using the DOI theory (Rogers, 2003).  The process of development of this 
online questionnaire, including field testing and pilot testing, was based on DeVellis’s 
guidelines for scale development (DeVellis, 2003) and will be discussed in a future 
manuscript.   All items in the final questionnaire were distributed to nine genetic content 
experts for clarification and for scoring content validity. After content validity scoring by 
the nine genetic content experts, follow-up with each expert was done to establish face 
validity. Questionnaire item content validity was 0.78 with overall questionnaire content 
validity of 0.64.  Inter-rater reliability was scored only for the first three constructs 
(Awareness-Knowledge, Innovation and Communication) with a score of 0.64. The Time 
construct was measured using the Individual Innovativeness Scale with an established 
Cronbach’s alpha of 0.94, used with permission (Hurt, et.al. 197). Additionally, the final 
questionnaire version was field-tested by ten Clemson University NPs, in order to 
determine the questionnaire logistics; readability, item burden and ease of administration.  
The questionnaire consisted of 72 questions, divided into five parts, each part 
reflecting the identified constructs and concepts used from the DOI theory to create the 
questionnaire. The Awareness-Knowledge construct was measured with 12 questions, the 
Innovation construct with 16 questions and the Communication construct was measured 
with six questions.  The Time construct consisted of 20 questions and the Social System 
construct consisted of 18 demographic questions describing the characteristics of the NPs 
who volunteered to participate in the study.  
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Questions included in the questionnaire were mainly true/false and 5-point Likert-
type scales, ranging from “strongly agree” to “strongly disagree”.  Some revised 
questions with the same item stem had answers that were collapsed in multiple choice 
options that included “all of the above” and “none of the above” to lessen item burden 
and redundancy.  Participants were encouraged to complete the entire questionnaire in the 
invitation to participate portion of the questionnaire. Table 4.3 shows the breakdown of 
questionnaire items according to constructs and concepts operationalized from the DOI 
theory. 
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Table 4.3  
Questionnaire Items 
Construct Concept # of Items 
Awareness-Knowledge 
 
 
 
Innovation 
 
 
 
 
 
Communication 
 
Time 
Awareness cognition 
How-to-knowledge 
Principles knowledge 
 
Relative Advantage 
Complexity 
Compatibility 
Trialability 
Observability 
 
Communication Channels 
 
Innovativeness Inventory 
1 
8 
3 
 
1 
4 
4 
2 
5 
 
6 
 
20 
Social System Demographics 18 
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Human subjects and research approval procedures 
Prior to each step of the questionnaire development and data collection, the study 
protocol received approval from the Clemson University Institutional Review Board 
(IRB).  Before beginning the online questionnaire, participants were informed, by e-mail 
invitation, of the study’s purpose.  The invitation also included an informed consent 
stating that no identifying information would accompany their questionnaire submission.  
The ten Clemson University NPs who field-tested the questionnaire were excluded from 
participation in this pilot study.  
Data collection procedures  
 A convenience sample of 239 nurse practitioners, taken from the two nurse 
practitioner associations’ membership, was invited by e-mail to participate in the pilot 
study.  Informed consent preceded the online, self-administered questionnaire; activated 
using Qualtrics® survey software.  No individual incentives were offered for 
participation; however, NPs who completed the questionnaire were entered into a 
drawing where four members of each NP association would have their 2014 annual dues 
paid. 
 The data collection spanned from October 28, 2013 to November 18, 2013, 
before the holiday season commenced and after receiving IRB approval for the pilot 
study. E-mail reminders were sent to the sample population weekly for two weeks.  
Additionally, postcards that contained the study’s purpose and Qualtrics® link were 
distributed during the data collection time period at the two NP associations’ monthly 
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meetings, both held on November 12, 2013.  Data were collected and stored in a 
password-protected file only accessible to study personnel.  
Data Analysis 
Data were exported from the Qualtrics® questionnaire into Microsoft® Excel 
2013 and SPSS® 21 software. A biostatistician was consulted about the appropriate 
statistical analyses. Fisher exact and chi-square analyses assessed NP’s awareness of 
GINA with the study variables of interest to answer the research questions. Demographic 
statistics for categorical and continuous data included means, standard deviations, and 
frequencies.  Missing data occurred for a few demographic questions, such as gender 
(N=2) and for the specialized practice setting question (N=9). The missing data did not 
affect the statistical results. All p values are two-tailed and presented without adjustment. 
Statistical significance of comparison was set at p < .05. 
Results 
  The final sample consisted of 65 NP participants who submitted completed 
questionnaires for a 27.20% response rate. The participants were 97 % female and 3% 
male. The mean age of the participants was 43.2 years with a standard deviation of 16.2 
years. Mean years as an NP was 8.51 years with a standard deviation of 2.57 years.  
Participant demographic and clinical setting characteristics are presented in Table 4.4  
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Table 4.4 
Participant Demographics of the Study Sample (N=65) 
Variable N % 
Gender 
    Male 
    Female 
 
Age (categories) 
    26-35 years 
    36-45 years 
    46-55 years 
    56-65+ years 
  
 
Race/Ethnicity 
    Asian American 
    Black, not Hispanic 
    White, not Hispanic 
    Other-not specified 
 
Years of experience as an NP 
    0-5 years 
    6-10 years 
    11-15 years 
    16-20+ years 
   
 
Employment Status 
    Full time (> 40 hrs./week) 
    Part time (< 40 hrs./week) 
    Retired 
    Seeking employment 
    Not seeking employment 
 
Employment Setting 
    Ambulatory/outpatient/primary care office 
    Retail clinic (e.g., Walgreen’s, CVS) 
    OB clinic 
    Emergency Department 
    Employee health clinic 
 
2 
61 
 
 
11 
12 
23 
19 
 
 
 
1 
2 
61 
1 
 
 
25 
8 
16 
16 
 
 
49 
13 
1 
1 
1 
 
 
36 
4 
1 
4 
2 
1 
 
3% 
97% 
 
 
17% 
18% 
35% 
30% 
 
 
 
2% 
3% 
94% 
2% 
 
 
38% 
12% 
25% 
26% 
 
 
75% 
20% 
2% 
2% 
2% 
 
 
55% 
6% 
2% 
6% 
3% 
2% 
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    Extended/long-term care facility 
    Skilled nursing facility 
    Intensive care/acute care 
    In-patient hospital unit/hospitalist 
    Occupational health 
    Educational 
    Non-traditional setting 
    Other setting 
 
Site 
    Urban area (> 50,000 population) 
    Urban cluster Urban cluster (2,500 to < 50,000 population) 
    Rural (<2,500 population) 
2 
1 
7 
3 
1 
2 
1 
 
 
47 
15 
2 
 
3% 
2% 
11% 
5% 
2% 
3% 
2% 
 
 
73% 
23% 
3% 
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Awareness of GINA and NP Education Preparation 
NPs’ awareness of GINA was compared to NP terminal education preparation, 
using Fisher’s exact test, since the sample was of sufficient size for a more accurate 
comparison.  Of the 22 participants who were aware of GINA, 19 possessed a master’s 
degree in nursing as their terminal nursing preparation as compared with three of the 
respondents who possessed either a PhD or DNP degree. There was no participant that 
held an EdD degree.  One NP participant had a NP certificate as a terminal nursing 
degree but was not aware of GINA, so that participant was excluded from the cross 
tabulations of statistics. Although percentages indicate that NPs with a PhD or DNP 
included a higher percentage of NPs aware of GINA, the Fisher’s exact test yielded a p-
value = 0.6837. Thus there was not a statistically significant relationship between 
awareness of GINA and NP terminal academic preparation (Table 4.5). 
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Table 4.5  
Comparison of Awareness of GINA and NP Terminal Academic Preparation (N=64*) 
NP Terminal Academic Preparation 
Awareness of GINA Master PhD or DNP Total  Fisher’s 
Exact  
p-value 
Yes 19  3  22  0.6837 
No 38 
 
4 42 
 
  
 
        *n=1 missing, certificate education preparation excluded 
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Awareness of GINA and Clinical Specialty Practice 
Responses to the question asking about “specialized practice setting” were 
divided into two groups ty the researcher and a genetic epidemiologist: those specialized 
practice setting where germline genetic testing is common, compared with settings where 
germline testing is uncommon. 
Specialized NP clinical practice settings where germline genetic testing is 
common included:  genetics, neonatal, pulmonary, cardiovascular (including cardio-
thoracic), gastroenterology, and psychiatric, internal medicine, oncology (including 
surgical and hematological oncology). Uncommon NP clinical specialty practice settings 
included renal, family practice, adult/gerontology, neurosurgery, infectious disease, 
orthopedics, urology, hospice, retail outpatient, clinical trials, emergency room, young 
adult, college, and military practice settings.  
Percentages for NPs in specialty clinical practice awareness of GINA versus those 
NPs in specialty clinical practice not aware of GINA were similar.  Chi-square analysis 
for this comparison resulted in x
2
 = 0.1275 with an associated p-value = 0.7211 indicating 
no statistical significance between awareness of GINA and their clinical specialty area 
(germline genetic testing common versus uncommon) (Table 4.6). 
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Table 4.6  
 
Comparison of Awareness of GINA and NP Clinical Specialty Practice with Common vs. 
Uncommon Use of Germline Genetic Testing (N=56*) 
 
NP Clinical Specialty Practice with Common vs. Uncommon Use of Germline Genetic 
Testing 
 
Awareness of GINA Common Uncommon Total x
2
 p-value 
Yes 6  13 19 0.1275 0.7211 
No 10  27  
 
37   
     * n=9 missing 
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Comparison of Awareness of GINA and Years of NP Clinical Practice 
Since GINA was signed into legislation in 2008 and enacted in 2009, this study 
explored whether NPs who started clinical practice as an NP in the last five years might 
have an increased awareness of GINA than their peers who have been in NP clinical 
practice six or more years.  The results indicated that 7 out of the 22 participants (28%) 
who were aware of GINA had been in NP clinical practice less than 5 years. However, 
those in NP clinical practice six or more years, 15 out of 22 participants (37.5%) were 
more aware of GINA. However, the results from this comparison were not statistically 
significant with an x
2
=0.6201 with p=.4310 (Table 4.7). 
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Table 4.7 
Comparison of Awareness of GINA and Years of NP Clinical Practice (N=65) 
Years of NP Clinical Practice 
Awareness of GINA < 5 years >6 years Total x
2
 p-value 
Yes 7 15  22 0.6201 0.4310 
No 
 
 
18  
 
 
25 
 
 
43   
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Comparison of Awareness of GINA and Age of the NP 
Age of the NP participants was measured in age intervals.  There were no 
participants who were younger than 26 who participated in the study.  There was one 
participant who was older than 65 and was collapsed in the 56-65+ interval range. The 
results indicated that the 36-45 years of age interval had the highest percentage of NPs 
aware of GINA (50%) and also held the lowest percentage of NPs (50%) not aware of 
GINA. However, there was not statistical significance that age of the NP played a role in 
the NP’s awareness of GINA, since x2 = 2.101 and p = 0.552 (Table 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80 
Table 4.8  
Comparison of Awareness of GINA and Age of the NP (N=65) 
Age of the NP in Years 
Awareness of GINA     26-35         36-45       46-55        56-65+     Total   x
2
        p-value 
 
  Yes                              3                    6                8               5              22    2.101     0.552 
 
   No                              8                     6               15             14             43 
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Comparison of Awareness of GINA and Time (Adopter Category of the NP) 
Based on Rogers’ Diffusion of Innovations Theory, the Time construct concerns 
itself with innovativeness, operationalized as the degree to which a NP in South Carolina 
is relatively earlier in awareness of GINA than other NPs in South Carolina.  New 
innovations can be diffused either in a planned or spontaneous manner and then, are 
either adopted or rejected by individuals (Rogers, 2003, p. 6) Diffusion is bound, not by 
the innovation, but by the potential adopters of the innovation and their social system 
(Rogers, 2003, p. 475).  This willingness of an individual, within a social system to adopt 
a new idea over time, can be categorized into five adopter categories or groups:  
innovators, early adopters, early majority, late majority and laggards or traditionalists 
(Rogers, 2003, p 283-284).  
According to the DOI theory, innovators are typically adventurous and like trying 
out new ideas.  Early adopters follow the innovator’s decision to reject or adopt the 
innovation. The early majority, usually the largest adoption section, is followed by the 
late majority and the last group, laggards or traditionalists (Rogers, 2003, pp. 283-284.)  
These five different adopter groups of an innovation over time have historically 
been represented graphically as bell-shaped curve, while the overall process of diffusion 
of an innovation may be represented by an S-shaped curve distribution (Rogers, 2003, 
p.12). Variations in “S” slopes have been shown to be dependent on the length of time it 
takes members of a social system to fully adopt an innovation (Rogers, 2003, p. 12).  The 
S-shaped diffusion curve increases dramatically, when 10-20 percent of an innovation is 
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diffused and adopted by a social system.  This typically occurs when communication 
channels of a social system are fully activated (Rogers, 2003, p. 12) (Figure 4.1).   
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Figure 4.1  
Adopter of Innovation Category with Diffusion of Innovation over Time 
Adopter Category, percent of population (blue line) 
Diffusion of Innovation over Time (yellow line) 
Adapted from Rogers, 2003.  
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The Time construct for this study was measured using the Individual 
Innovativeness Scale with an established Cronbach’s α =0.94 (Hurt, et al., 1977).  The 
adopter category was scored for each NP participant who was aware of GINA, per the 
scales’ guidelines (Hurt et al., 1977). Interestingly, the results from this pilot study results 
identified a similar reliability measure with a Cronbach’s α = 0.86.  
Of the 22 NPs who are aware of GINA, results indicated that eight NPs scored in 
the “early adopters” or in the “early majority” (36% each), while six NPs scored in the 
“late majority” category (24%).  There were no NPs who scored in the “innovator” or 
“laggard” category.  The “early adopters” and “early majority” categories were collapsed 
into one category that represents the left half of a bell curve, while the “late majority” 
category represented the right half of the bell curve based on Rogers’ DOI theory. 
Although not statistically significant with an x
2
 = 1.759 for a p = 0.185, the adoption of 
the innovation curve by this small sample of NPs aware of GINA, may be more similar to 
the DOI theory’s adoption of the innovation curve, presented earlier in this chapter, if a 
larger sample of NPs had participated in the study (Figure 4. 2) (Table 4.9). 
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Table 4.9 
Comparison of Awareness of GINA and Time (Adopter Category of the NP) (N=65) 
Adopter Category of the NP 
Awareness of GINA        Early            Late          Total                 x
2
        p-value 
  Yes                                       16               6                22                 1.759      0.185 
   No                                       24              19               43      
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Figure 4.2  
Time: Awareness of GINA among NPs 
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Communication Channels Used to Gain More Information about their Clinical 
Practice 
Which mass and interpersonal communication channels all NP participants, those 
who are aware and those who are not aware of GINA, would use to find more 
information about their clinical practice, are useful to developing educational avenues to 
diffuse GINA to NPs, and eventually into their clinical practice. These same 
communication channels could also be the same communication channels that NPs could 
use to find out information concerning GINA.  Rogers’ DOI theory implies that 
information that increases awareness of GINA rarely comes from a communication 
channel they actively seek; that information about GINA may be actively sought after 
NPs are aware of GINA existence, that NPs would know which communication channels 
to utilize to provide information about GINA to them (Rogers, 2003, pp. 202-203). 
Concerning mass media communication channels, the Internet and online 
website/search engine were the most favored forms of mass communication channels 
used by all participants aware of GINA (N=15 or 68.2% of aware participants), followed 
by a peer-reviewed journal (N=13 or 59% of aware participants). The favored mass 
communication channels for NPs not aware of GINA were the same mass communication 
channels of the aware participants: Internet (N=29 or 69%), online website/search engine 
(N=27 or 64.3%) and peer-reviewed journal (N=20 or 46.7%). 
The two interpersonal communication channels selected by the NPs of both the 
aware and unaware groups to find more information about GINA included attendance at 
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professional meetings (N=52 or 81.3% of all participants) followed by face-to-face 
workshops or lectures (N=45 or 70.3% of all participants). 
Effect size was determined for all communication channels used by NPs as a way 
of quantifying the size difference between the utilization of mass media and interpersonal 
communication channels by the aware and unaware NP groups. The type of effect size 
statistic used for these study results was the phi coefficient (φ), which serves as a 
function of both the chi-square (x
2
) and the total sample size (N=65). The effect size 
statistics for communication channels between aware and not aware NP groups range 
from -0.311 to 0.115, (with a phi coefficient (φ) = 0 indicating independence) between 
communication channels used and awareness of GINA by NPs (Cohen, 2001, p. 653).  
Thus the effect size for both the mass media and interpersonal communication channels 
used by NPs who were aware of GINA versus NPs who were not aware of GINA is not 
statistically significant (See Table 4.10). 
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Table 4.10  
Communication Channels Used by NPs to Gain More Information about their Clinical 
Practice  
 
                          Communication Channels Used by NPs to Gain Information 
Channel NPs Aware 
of GINA 
N         % 
(N/Total N) 
NPs Not 
Aware    
of GINA 
N           % 
(N/ Total N) 
Effect Size  
(Phi 
coefficient) 
φ 
 Total # of 
Participants 
N          % 
Mass Media 
Internet 
 
15      68.2 
 
29         69.0 
 
-0.009 
  
44        68.8 
On-line 
website/search 
engine 
15      68.2 27         64.3 0.039  42        65.6 
Peer-reviewed 
journal 
13      59.0 20         47.6 0.109  33        51.6 
Genetic association 
website 
9        40.9 15         35.7 0.051  24       37.5 
Association 
website/newsletter 
 
5        22.7 6           14.3 0.115  11      17.2 
Interpersonal       
Professional 
meeting 
18     81.8 34         81.0 0.011  52      81.3 
Workshop/lecture 17     77.3 28         66.7 0.110  45      70.3 
Face-to-face 
communication 
8       36.4 13         31.0 0.055  21      32.8 
Formal education 
class 
8       36.4 16        38.1 -0.017  24      37.5 
Pharm/medical 
sales rep 
0        0 10        23.8 -0.311  10       15.6 
Texts from peers 0        0 2          4.76 -0.130  2         3.13 
E-mail from peers 2       9.09 5          11.9 -0.043  7         10.9 
 
Total 
 
    22 
 
42 
 
-0.313 
  
64* 
*N=1 data missing from non-aware participant 
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Limitations 
 Data collection from a small, self-selected, convenience sample size in a pilot 
study has inherent limitations.  These limitations are not limited to: the small sample may 
not be representative of the NP population in South Carolina, the number of questions 
may have deterred some NPs from participating in the study and NPs may have felt 
intimidated by their lack of awareness of GINA, so they self-selected themselves from 
participation in the survey.  Additionally, members of the volunteer sample were 
affiliated with one of two NP associations in South Carolina, located in the Southeast and 
Northwest corners of South Carolina.  Therefore, this distribution may not reflect the 
awareness and knowledge of GINA by NPs in a clinical practice located in other parts of 
the state. 
Implications for Practice and Conclusions 
This pilot study possesses the following strengths: 
 A new theory-based conceptual approach for examining the awareness of 
GINA in the nurse practitioners is introduced, using defined research 
questions. 
 The created online questionnaire uses a well-known, well-researched 
theory, Rogers’ Diffusion of Innovations theory 
 This empirical research study draws upon previous research assessing 
awareness of GINA in consumers, genetic counselors and physicians. 
 The initial results data can be used to determine sample size calculations 
for subsequent studies assessing the awareness of GINA among NPs. 
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The pilot study did find that the majority of NPs composing the sample group in 
South Carolina are not aware of GINA.  There may exist clinically and statistically 
significant relationships between awareness of GINA and recently graduated NPs with 
Master’s degrees and those NPs employed in specialized clinical settings; however, 
undue significance of the results cannot be placed without formal power calculations as 
the research sample population was too small to draw any conclusions.   
Awareness of GINA was not shown to be statistically significant when compared 
to age of the NP and their adopter category.   However, the data indicate that NPs in the 
36-45 years of age interval were more aware of GINA than other age groups.  Also, 
although no NPs who were aware of GINA scored in the “innovator” category, neither 
did any of the NPs score in the “laggard” or “traditionalist” category. 
Lastly, NPs, both aware and unaware of GINA, indicated they use similar mass 
media and interpersonal communication channels to gain awareness about GINA.  The 
effect sizes of these communication channels indicate that awareness of GINA is not 
dependent on which communication channel the NPs chose to utilize.  Thus, in planning 
to disseminate information of and about GINA to NPs, the mass communication channels 
of the Internet, online website/search engines and peer-reviewed journals should include 
information about GINA.  Interpersonal channels NPs use the most, professional 
meetings and workshops/lectures are the best way to diffuse information about GINA. 
Future Research 
Future research opportunities are identifiable.  These opportunities include to 
conduct additional pilot studies, expanding on Roger’s DOI theory using antecedents of 
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the knowledge stage and determining if there are statistically significant relationships 
between the antecedents of knowing and awareness-knowledge of GINA. Results of this 
subsequent study could then determine if a larger research study, first utilizing NPs and 
then expanding to other nurses with advanced degrees (certified registered nurse 
anesthetist, clinical nurse specialist and certified nurse midwife) could be studies 
concerning awareness of GINA. Also, a NPs’ knowledge of essential genetic and 
genomic competencies that may be studied to see if knowledge of these competencies 
play a critical role in the diffusion of GINA. The current questionnaire needs to be 
validated and shown to be reliable, which would require more rigorous methods of 
measurements.   The ultimate goal of this researcher is to use a reliable and validated 
online questionnaire to assess awareness of GINA in NPs nation-wide.  
Summary 
This pilot study contributes to the general body of knowledge concerning 
awareness of GINA in healthcare professionals.  In particular, this pilot study is the first 
known research to study awareness of GINA in NPs.  Study findings suggest that 
awareness of GINA was not statistically associated with a NP’s terminal nursing 
education, their clinical specialty, their years of clinical practice, their age, their adopter 
category or which communication channels NPs use to find information. However the 
descriptive statistics did indicate that NPs in clinical practice longer may have more 
awareness of GINA, particularly in the 36-45 age range.  The adopter category indicated 
that NPs who were aware of GINA did not score in the “innovator” or “laggard” 
category, however since the questionnaire was self-selective and self-administered, the 
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findings might be different if that NP was evaluated by a peer. Finally, this research 
indicated what mass and interpersonal communication channels NPs use to find 
information about GINA.  This information can and will be used to further disseminate 
GINA information to NPs, so they can, in turn, further disseminate that information to 
their patients and families. 
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CHAPTER FIVE 
SYNTHESIS 
 
 The three manuscripts that make up this dissertation focus on awareness of 
discrimination based on genetic information. Nurses have a critical role in educating, 
counseling and advocating for their patients and families as they make genetic and 
genomic-based healthcare decisions.   The patients’ personal genetic information 
challenge nurses to not only understand the ethical issues associated with protecting and 
maintaining confidentiality of a patient’s health information, but also the legal issues in 
order to prevent discrimination based on genetic information (Cassells, Jenkins, Lea, 
Calzone, & Johnson, 2003).  
The first manuscript takes a critical look at the application of GINA for nursing 
professionals in oncology who work with cancer patients and their families with a system 
specific diagnosis of these inherited genetic-based malignancies.  The manuscript is 
specifically written for the nursing profession; advising oncology nurses to be “aware and 
beware of GINA” as they integrate GINA into their clinical practice.  Also included is a 
discussion on how GINA amends previously passed and current federal anti-
discrimination health laws. The manuscript concludes with a discussion concerning the 
awareness of GINA by healthcare professionals since GINA’s provisions were enacted in 
2009, under a new presidential administration.  Since then, the Obama/Biden Plan (2009) 
has been introduced, which prohibited private insurance companies from denying 
individuals healthcare coverage based on pre-existing health conditions, including pre-
existing genetic disease, such as cancer. 
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 The need for the usefulness of awareness of GINA is exemplified by publication 
of the first manuscript by the Clinical Journal of Oncology Nursing (CJON). The 
manuscript was selected as the continuing education article of the month for CJON, 
recorded as an Oncology Nursing Society podcast interviewing the author about the need 
to be aware of GINA, and was picked up by Breast Cancer Network News, which 
includes news on “current breast cancer research, treatment, symptoms, causes and risk 
factors to educate the public and healthcare providers (Breast Cancer News Network, 
2011). The five citations from this publication, including one of the research studies in 
the review of literature for the pilot study, imply the importance other scholars have 
credited to this article as a pinnacle of GINA awareness.  Even with professional and lay 
support of the importance of awareness of GINA, this researcher wanted to further 
examine the concept of “awareness of discrimination based on genetic information”, 
utilizing a concept analysis method.  
The second manuscript analyzes the “awareness of discrimination based on 
genetic information” concept by utilizing and adding to Roy’s Adaptation model and 
Wilson’s method of concept analysis, defining the concept for use in nursing with a 
model case, contrary case and borderline case as examples of discrimination based on a 
patient’s genetic make-up (Hupcey, Morse, Lenz, & Tason, 1996; Phillips, 2010).  The 
resultant operational definition, “to know differences against people or distinguish 
between people based on their ancestral, heritable, communicated facts or knowledge” 
for the concept utilizes terms, key words and concepts that are also found in Rogers’ 
Diffusion of Innovation theory (see Table 4.2).  The DOI theory also guided the 
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development and direction of the pilot questionnaire in the third manuscript, the research 
portion for this dissertation (Steck, 2012).  
  The third manuscript begins with a literature review to justify the need to assess 
the awareness of GINA among NPs; that NPs have been overlooked as a significant 
group of healthcare professionals who may use GINA’s provisions and limitations when 
providing patient care. The creation of a questionnaire based on the operational definition 
of the awareness concept in addition to elements from Rogers’ DOI theory was necessary 
in to empirically assess NPs’ awareness of GINA.  A 72 item online questionnaire was 
thus created and tested for item and questionnaire content validity and inter-rater 
reliability, guided by Rogers’ DOI theory. Because the DOI theory was previously used 
as a guide to establish the genetic and genomic competencies for nurses with 
undergraduate degrees, and associated with the American Nurses Association (ANA) 
“Essential Genetic and Genomic Competencies for Nurses with Graduate Degrees, the 
elements of ethics and policy in these competencies was used as the ethical framework 
for this dissertation (Consensus Panel of Genetic/Genomic Competencies, 2009). 
Originally, it was believed the pilot study, using the DOI theory to formulate this 
questionnaire and guide the study, outcomes would contribute to understanding what 
variables influence the diffusion of GINA among NPs in South Carolina.   The research 
questions in this study, utilized three of the four constructs taken from Rogers’ Diffusion 
of Innovations (DOI) Theory: time, communication and social system. The innovation 
construct, developed using the DOI theory, incorporated the perceived attributes or 
concepts of relative frequency, compatibility, complexity, triability, and observability, 
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were included in questionnaire items asking about NPs’ attitudes toward the use or 
potential use of GINA in their clinical practice.  Since the DOI theory indicates that the 
characteristics of innovations, as perceived by individuals, helps to explain the different 
rates of adoption of an innovation, the collected data can be used to answer research 
questions in follow-up studies that explore how NPs perceive the attributes of GINA in 
relationship to their adoption of this law. 
Six specific variables used to answer the research questions in the pilot study to 
determine awareness of GINA among the NP participants, have been discussed: 1) the 
NP’s terminal academic degree, 2) the NP’s specialty practice, 3) years of the NP clinical 
practice, 4) age of the NP, 5) adopter category of the NP and 6) the communication 
channels NPs would use to obtain information concerning GINA. To re-emphasize, these 
research questions were built based on the four main elements of the DOI theory (Rogers, 
2003, p.11). 
To answer the first four research questions, the data were cross-tabulated to 
analyze if awareness of GINA by the NPs in the sample had any statistically significant 
relationships with the NPs’ demographics under investigation. Rogers (2003) 
conceptually defined a social system as a “set of interrelated units that are engaged to a 
joint problem solving to accomplish a common goal” (p. 23).  This conceptual definition 
was operationalized by the researcher for this study to define a social system as a ‘set of 
interrelated characteristics/demographics of NPs in South Carolina that possess 
awareness of GINA’. Collected data were analyzed to answer the following four research 
questions: 
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1. Is there a relationship between terminal academic degrees (Master versus PhD 
and DNP) and awareness of GINA? 
2. Does awareness of GINA differ among clinical specialties where germline 
genetic testing is common versus clinical specialties where germline genetic 
testing is not common? 
3. Is there a difference in awareness of GINA depending on years of NP clinical 
practice? 
4. Is there a difference in awareness of GINA depending on the age of the NP? 
Fisher’s exact and chi-square analyses did not find any statistically significant  
relationships between awareness of GINA among NPs with the demographic questions 
that queried the NP’s terminal academic degree, years of NP practice, age of the NP or 
the NP’s clinical specialty practice. However, the demographic statistics using 
frequencies indicated that NPs with a PhD or DNP had a higher percentage of awareness 
of GINA than NPs with terminal master’s degrees.  NPs who had been practicing for 
more than 6 years, indicated they had greater awareness of GINA than newly-graduated 
NPs in the last5 years who may have had the 2009 essential competencies for nurses with 
advanced degrees incorporated in their nursing curricula. NPs in the 36-45 age range also 
had the highest percentage of awareness in any NP age interval.  No interrelated 
characteristic could be found in the data concerning NP clinical specialties where 
germline genetic testing is common versus the NP clinical specialties where germline 
genetic testing is not common.  The data indicated this question, if used in subsequent 
studies, needs further clarification regarding what is intended to be measured. 
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When examining the research question that correlates awareness of GINA with 
NP adopter category (the Time construct), Rogers’ DOI theory states that “the units in a 
social system are not all identical in the behavior”, that the structure of a social system, in 
this case, the patterned arrangement of NPs in the system gives regularity and stability, 
allowing the researcher to predict behavior in the social system with some degree of 
accuracy (Rogers, 2003, p. 24). Although there was not a statistically significant 
relationship between the adopter category of the NP and awareness of GINA, the data 
indicates that 16 out of 22 NPs who were aware of GINA scored either as early adopters, 
the second fastest category of individuals who have awareness of GINA (behind 
innovators) or the third category, early majority, individuals who have awareness of 
GINA, the average member of the NP sample social system.  Only six out of 22 in the 
aware NP group scored in the late majority category, made up of individuals who are 
aware of GINA after the average NP in the sample (Rogers, 2003, p.22).  Although time 
has historically been used an independent variable in the DOI theory, the measurement of 
this dimension has been under scrutiny in dissertation research, since adopter category is 
scored, based self-report by the participant. However, this construct would be important 
to be included in subsequent studies concerning the innovation-decision process where a 
NP passes from awareness of GINA to the adoption or rejection of usage in clinical 
practice. In addition, the inclusion of time (adopter category) could assist in the 
determination of GINA’s rate of adoption among NPs and measured as the number of 
NPs who adopt GINA in a given time period (Rogers, 2003, p. 20).  
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The research question that explores if a relationship exists between an NP’s 
awareness of GINA and the communication channels (mass media and interpersonal) 
they use to search for information about clinical practice issues, though not yielding 
statistically significant analysis for such a relationship and not statistically significant for 
effect size, still provides valuable information to this researcher for future diffusion of 
GINA awareness in NPs. Rogers defines a communication channel as “the means by 
which messages get from one individual to another.” (Rogers, 2003, p. 18). In the 
beginning, communication channels for this study were operationalized to be ‘means by 
which awareness of GINA is shared from one individual to an NP’.  This transfer of 
information occurs most frequently between two individuals who are homophilous in 
certain attributes such as education and a mutual language, like the NPs in this sample.  
Thus, the transfer of information about GINA’s existence potentially has a greater effect 
in attaining awareness, knowledge and adoption or rejection of GINA in clinical practice 
of a NP (Rogers, 2003, p.19). 
The effect size and frequencies indicated that NP groups in the sample, those 
aware of or unaware of GINA, used the Internet, online website/search engines and peer-
reviewed journals as the top three mass media communication channels and also used the 
same top two interpersonal channels, workshops, formal meetings and lectures to gain 
information used in their clinical practice.  Before subsequent research is performed, 
using a different sample of NPs, this researcher plans to effectively diffuse information 
about GINA through these mass media and interpersonal communication channels as 
identified in the pilot study results. 
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In addition to the use of Rogers’ DOI theory to guide development of the 
questionnaire and to guide the research portion of this dissertation, these three 
manuscripts used the essential competencies as a guiding ethical framework to utilize 
evidence-based research to guide other research and clinical practice.  The use of “The 
Essentials” demonstrate how the incorporation of the genetic and genomic competencies 
for nurses with graduate degrees can be accomplished in the education, clinical practice 
and research arenas (Consensus Panel on Genetic/Genomic Nursing Competencies, 
2009). 
The first manuscript describes a mechanism to address the important essential 
competency, “All nurses with graduate degrees in nursing inform health care and 
research policy related to ELSI issues in genetics/genomics” (Greco, Tinley, & Siebert, 
2011).   In the second manuscript, the author develops a concept analysis as a solid and 
meaningful foundation to explain “awareness of discrimination based on genetic 
information” as it related to GINA, meeting the competency that nurses with graduate 
degrees need to develop a solid foundation in genetic/genomics in order to provide 
quality care to their clients (Greco, Tinley, & Siebert, 2011).   Using information derived 
from the first two manuscripts as a foundation, the third manuscript describes the 
development, implementation, and analysis of a questionnaire that collects data to 
determine if NPs are aware of GINA, an initial step in meeting the competency that 
nurses at the doctoral level are expected to provide leadership in the conduct of research 
and translate genetic findings into clinical practice (Greco, Tinley & Siebert, 2011). 
Adding to the rigor of this pilot study, the questionnaire developed for this study used 
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selected appropriate constructs from terms in the concept analysis that also served as 
main elements in the DOI theory, the same theory used to develop the essential 
competencies in genetics/genomics for nurse with graduate degrees (Greco, Tinley & 
Siebert, 2011). 
 As this research study was being developed, enforcement of GINA’s provisions 
and limitations was examined in the legal arena. Two recent cases of enforcement of 
GINA’s employment provisions have been brought to trial. One of the employers was 
found guilty and paid a $50,000 fine and agreed to provide anti-discrimination training to 
human resource employees.  The employer in the other case was not found guilty of 
discrimination based on genetic information (Trottman, 2013). The Wall Street Journal 
also reported in July, 2013 that 170 GINA claims are currently being reviewed by EEOC 
regulators (Trottman, 2013).  While the research data were being analyzed, an NP from 
the South Carolina Upstate area phoned the researcher to discuss a case where the 
insurance company was demanding genetic testing results from a young patient with no 
cancer diagnosis, but a positive BRCA mutation, placing the patient at highest risk for the 
development of breast cancer (J.A. Eggert, personal communication, December 11, 
2013). As these cases concerning the enforcement of GINA’s provisions and limitations 
are publically reported, as well as presented in the local healthcare arena, the awareness 
and knowledge of GINA may be enhanced not only by all consumers, but also consumers 
of health care and their professionals. It also documents the researcher is viewed as an 
expert in awareness and knowledge about GINA when specific information is needed to 
enhance the long-term health and well-being of patients.  
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  The overall outcome of this pilot study indicated that among NPs in the sample, 
the majority are not aware of GINA’s existence.  Awareness of GINA among these NPs 
was not statistically correlated with NP’s terminal nursing degree, the NP’s years of 
clinical practice or the clinical specialty where they are practicing. Additionally, the 
awareness of GINA was not statistically correlated with the NP’s age and adopter 
category. The communication channels that NPs who were aware of GINA would use to 
find more information about GINA did not indicate a statistical relationship with the 
communication channels that NPs that are not aware of GINA would use.  The top three 
mass media and top two interpersonal communication channels used by both the aware 
and not aware group were similar. Finally, these study results can guide diffusion of 
GINA’s provisions and limitations using targeted communication channels that NPs use 
to gain information relevant to their clinical practice.   
This pilot study was not only designed to collect and analyze data about 
awareness of GINA among NPs in South Carolina, but it also tested the logistics of using 
a newly-created online questionnaire to assess awareness of GINA among NPs. The 
results of this pilot study should be interpreted cautiously as the sample may not be 
representative of the general population of NPs in clinical practice in South Carolina.  
However, this pilot study provides a foundation on which to build the next steps to 
further assess the pilot questionnaire.  Results obtained from this study will also be used 
to refine and redesign the study method prior to conducting another research study, with a 
larger sample of different NPs first in other areas of South Carolina, then regionally, 
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moving towards, based on the results, the final goal of a national study assessing the 
awareness of GINA among NPs.  
Future researchers could also utilize the work in this dissertation, to incorporate 
concurrent research to investigate if graduate nursing faculties have fully integrated 
genetics and genomics, including information about GINA, into NP curriculums nation-
wide.   A recent article by Mardiegue, Edwards and Seibert (2013) revealed there are 
education gaps in genetic/genomic content taught to advance practice NP students; 
approximately 70% of faculty in 2010 felt comfortable teaching basic genetic/genomic 
concepts.  Related to this dissertation topic, it is not known if information concerning 
GINA is included in graduate nursing curricula.  Currently, the Genetics Literacy 
Assessment Instrument (GLIA) for undergraduate nursing students, does incorporate one 
GINA-related question, “Which of the following is a consequence of federal legislation 
enacted in 2008 entitled “Genetic Information Nondiscrimination Act (GINA)?” This 
inclusion can increase awareness of GINA among undergraduate nursing students, 
however, there is not a comparable instrument to measure genetics literacy in graduate 
nursing students (Bowling, Acra, Wan, Myers, Dean …Huether, 2008). 
The body of work in this dissertation represents not only the intellectual, physical 
and mental work of the researcher but also epistemological work, regarding how to 
conduct a concept analysis of a timely concept in healthcare, as well as the derivation of a 
questionnaire and subsequent pilot study using that questionnaire, based on selective 
parts of a well-known diffusion theory.  However, this researcher has only begun to 
examine the diffusion of GINA in the nursing discipline.  Ideas to add to this knowledge 
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base include conducting another concept analysis, for the awareness of discrimination 
based on genetic information, using either the Walker or Avant concept analysis methods.  
These other concept analysis methods identify antecedents related to the concept, some 
the same antecedents used in the DOI theory (Walker & Avant, p. 144). These 
antecedents could be incorporated in additional, more rigorous research study, utilizing a 
different, larger sample of NPs, with a reliable and valid questionnaire, assessing 
awareness of other innovations among nurses. 
Figure 5.1 reflects this researcher’s perspective of how programs of study on this 
topic evolve; as the personal awareness of GINA and personal genetic medicine evolves, 
the collecting and management of a patient’s genetic information has increased in 
importance.  Being able to predict what disease will most likely affect a patient, 
anticipate the monitoring of either the non- progression or progression of a patient’s 
genetically-derived disease, and being able to determine the most appropriate treatment 
for that patient based on their genetic make-up contribute to the advent of personalized 
genetic/genomic medicine (Feldman ,2012). By incorporating information about GINA in 
graduate nursing programs and NPs’ clinical practices, using the ethical framework 
provided by the essential competencies for genetics and genomics for nurses with 
graduate degrees, and by using the domains from Rogers’ DOI theory to evaluate those 
competencies, it is anticipated that awareness of GINA will continually evolve (Jenkins 
& Calzone, 2007) (see Figure 5.1). 
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Summary 
 No human possesses a perfect set of genes.  Every human may develop between 5 
to 50 health disorders due to their genetic make-up and these may also be potentially 
lethal (Slaughter, 2008).   Though lethal germline mutations may never be expressed in 
an individual, they may be passed onto the individual’s children (Slaughter, 2008).   
Approximately 13 million Americans are affected by at least 16,000 recognized genetic 
disorders (Slaughter, 2008; Tan, 2009).  Consequently, every American possesses various 
degrees of risk to develop genetically linked disorders in their lifetime and is at risk to 
experience discrimination based on their inherited genetic information (Slaughter, 2008). 
  The Genetic Information Nondiscrimination Act of 2008 (GINA) required 13 
years to pass both houses of Congress before it was signed into law, the same time span 
that was used to sequence the entire human genome (Tan, 2009). GINA is considered 
preemptive legislation; it anticipated that problems would arise as new discoveries were 
made in genetic science.  Additionally, GINA’s provisions may have helped accelerate 
the rate of genetic science discoveries by addressing individuals’ fears of discrimination 
based on their genetic information when they enroll in clinical research trials (Tan, 2009).   
 Even though the recently implemented Affordable Care Act of 2010 prohibits 
denial of health insurance coverage based on an individual’s genetic information, it only 
acts as a complement to GINA’s provisions.  GINA as a law is more stringent, since it 
prohibits health insurers from collecting genetic information and/or using it to establish 
individuals’ premiums (Feldman, 2012; National Human Genome Research Institute, 
2014). 
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However, healthcare providers should continue to collect genetic information as it 
can lead to a higher quality of patient care.  NPs, as healthcare providers in particular, 
need to be aware and knowledgeable about GINA as they translate genomics into clinical 
practice.  By understanding GINA’s provisions and limitations the NPs can better assist 
patients and their families to understand their personalized genomic-based health care.  
Awareness and knowledge of and about GINA will help NPs provide the complex, 
appropriate and equitable genetic health care that patients and their families deserve 
(Badzek, Henaghan, Turner, & Monsen, 2013) 
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Appendix B 
 
Final Questionnaire for Pilot Study 
Awareness of the Genetic Information Nondiscrimination Act of 2008 (GINA) in 
South Carolina Nurse Practitioners. 
 
1.I am aware that The Genetic Information Nondiscrimination Act of 2008 (GINA) is 
current law. 
 Yes 
 No 
 
2.I know how to use the definitions of genetic information found in GINA. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
3.I know how to use the provisions included in GINA. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
4.I know how to use the limitations included in GINA. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
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5.Protected genetic tests in GINA include: (choose any that apply) 
 mutations associated with hereditary cancers. 
 properties of an existing tumor that could help determine therapy for the tumor. 
 the Huntington disease mutation. 
 carrier screening for cystic fibrosis, sickle cell anemia, spinal muscular atrophy and 
Fragile X Syndrome. 
 all of the above. 
 none of the above. 
 I do not know 
 
6.GINA prohibits: (choose any that apply) 
 health insurers and employers from requesting that an individual take a genetic test. 
 employers from using genetic information in employment decisions. 
 employers from obtaining genetic information about an individual's family members. 
 health insurers and employers from using fetal genetic tests of a pregnant family 
member to make health insurance and employment decisions. 
 employers from acquiring genetic information inadvertently through conversations or 
electronic health records. 
 all of the above. 
 none of the above. 
 I do not know 
 
7.GINA does not apply to: (choose any that apply) 
 employers with less than 15 employees. 
 members of the United States  (U.S.) military. 
 veterans of the U.S. military, obtaining service through the Veterans' Administration. 
 healthcare services through the U.S. Indian Health Service. 
 all of the above. 
 none of the above. 
 I do not know 
 
8.GINA provides protection when qualifying for life insurance coverage, disability and 
long-term care insurance. 
 Yes 
 No 
 I do not know 
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9.GINA’s definitions of genetic information includes: (choose any that apply)  
 an individual's of family member's genetic test results 
 occurrence of genetic disease in an individual's family members. 
 an individual or family member's genetic tests results, while participating in a 
research study. 
 genetic counseling an individual or family member receives while participating in a 
clinical research study. 
 genetic education an individual or family member receives while participating in a 
research study. 
 all of the above. 
 none of the above. 
 I do not know 
 
10.The addition of GINA prohibits all health insurance issuers from denying coverage to 
an individual based on their genetic information. 
 Yes 
 No 
 I do not know 
 
11.GINA states that genetic information be treated the same as other private health 
information under Health Insurance Portability and Accountability Act of 1996 (HIPPA). 
 Yes 
 No 
 I do not know 
 
12.Violation of GINA's provisions is considered a federal offense. 
 Yes 
 No 
 I do not know 
 
13.The advantages of GINA far outweigh the disadvantages. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
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14.GINA is an easy law to understand.  
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
15.GINA can be difficult to use in my practice. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
16. GINA requires little genetic background knowledge to understand its provisions. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
17.GINA requires little legal and/or regulatory knowledge to understand its provisions. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
18.GINA is applicable to patients in general clinical settings. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
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19.GINA is applicable to patients in specialized clinical settings. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
20.GINA is compatible with all aspects of my work as a nurse practitioner. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
21.GINA is compatible with only a few aspects of my work as a nurse practitioner. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
22.I have had a great deal of opportunity to apply GINA's provisions in my clinical 
practice. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
23.I have not used GINA in my clinical practice. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
24. 
 Yes 
 No 
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25.Employment protections of GINA are applied in my workplace. 
 Yes 
 No 
 
26.GINA's health insurance protections are applied to my personal healthcare. 
 Yes 
 No 
 
27.Information about GINA is displayed in my practice setting. 
 Yes 
 No 
 
28.I have observed other healthcare professionals in my clinical practice using GINA. 
 Yes 
 No 
 
29.Which of the following mass-media channel(s) did you use to gain information about 
GINA? (Check all that apply) 
 Internet 
 radio/television 
 newspaper/magazine 
 peer-reviewed journal 
 on-line website/search engine (e.g. WebMD, Medscape, MayoClinic) 
 genetic websites (e.g Genetic Alliance) 
 association website/newsletter (e.g. NpAlert, AANP) 
 social networks (e.g. Twitter, Facebook, blogs, Wikis, discussion boards) 
 on-line continuing education courses/webinars 
 electronic health records (EHRs) 
 apps (e.g. Gene Screen, Gene Wall, Genetics4M) 
 other ____________________ 
 I have never looked for information about GINA 
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30.Which of the following mass media channel(s) do you use the most to gain 
information useful to your current clinical setting? (Check all that apply) 
 Internet 
 radio/television 
 newspaper/magazine 
 peer-reviewed journal 
 on-line website/search engine (e.g. WebMD, Medscape, MayoClinic) 
 genetic websites (e.g. Genetic Alliance) 
 association website/newsletter (e.g. NPAlert, AANP) 
 social networks (e.g. Twitter, Facebook, blogs, Wikis, discussion boards) 
 on-line continuing education courses/webinars 
 electronic health records (EHRs) 
 apps 
 other ____________________ 
 
31.Which of the following interpersonal channel(s) did you use to gain information about 
GINA? (Check all that apply) 
 face-to-face workshops/lectures 
 professional meetings 
 face-to-face communication (chats, consultations, reading notes in EHRs) 
 formal education classes 
 pharmaceutical/medical sales representatives 
 texts from peers 
 e-mail from peers 
 other ____________________ 
 I have never looked for information about GINA 
 
32.Which of the following interpersonal channel(s) do you use the most to gain 
information useful to your current clinical setting? (check all that apply) 
 face-to-face workshops/lectures 
 professional meetings 
 face-to-face communication (chats, consultations, reading notes in EHRs) 
 formal education classes 
 pharmaceutical /medical sales representatives 
 texts from peers 
 email from peers 
 other ____________________ 
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33.If I wanted to learn more about GINA I would use the following mass media channel 
(s). (check all that apply) 
 Internet 
 radio/television 
 newspaper/magazine 
 peer-reviewed journal 
 on-line website/search engine 
 genetic association website 
 association website/newsletter 
 social networks 
 EHRs 
 apps 
 other ____________________ 
 
34.If I wanted to learn more about GINA I would use the following interpersonal 
channel(s) (check all that apply) 
 face-to-face workshop/lecture 
 professional meeting 
 face-to-face communication 
 formal education class 
 pharmaceutical/medical sales representative 
 texts from peers 
 e-mail from peers 
 other ____________________ 
 
35.My peers often ask me for advice or information 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
36.I enjoy trying new ideas. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
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37.I seek out new ways to do things. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
38.I am generally cautious about accepting new ideas. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
39.I frequently improvise methods for solving a problem when an answer is not apparent. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
40.I am suspicious of new inventions and new ways of thinking. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
41.I rarely trust new ideas until I can see whether the vast majority of people around me 
accept them. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
 129 
42.I feel that I am an influential member of my peer group. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
43.I consider myself to be creative and original in my thinking and behavior. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
44.I am aware that I am usually one of the last people in my group to accept something 
new. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
45.I am an inventive kind of person. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
46.I enjoy taking part in the leadership responsibilities of the group I belong to. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
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47.I am reluctant about adopting new ways of doing things until I see them working for 
people around me. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
48.I find it stimulating to be original in my thinking and behavior. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
49. tend to feel that the old way of living and doing things is the best way. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
50.I am challenged by ambiguities and unsolved problems. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
51.I must see other people using new innovations before I will consider them. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
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52.I am receptive to new ideas. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
53.I am challenged by unanswered questions. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
54.I often find myself skeptical of new ideas. 
 Strongly Disagree 
 Disagree 
 Neither Agree nor Disagree 
 Agree 
 Strongly Agree 
 
55.What NP certification(s) (recognized in South Carolina) do you currently hold? (check 
all that apply) 
 Adult 
 Family 
 Pediatric 
 Acute care 
 Gerontology 
 Adult psychiatric and mental health 
 Family psychiatric and mental health 
 Women's health 
 Neonatal 
 Adult acute care 
 Advanced oncology 
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56.Nurse practitioner education preparation (highest level achieved) 
 Certificate 
 Bachelors 
 Masters 
 Doctor of Nursing Practice (DNP) 
 Doctor of Philosophy (PhD) 
 Doctor of Education (EdD) 
 
57.Highest degree, other than in nursing, achieved 
 PhD 
 EdD 
 Masters 
 Bachelors 
 None 
 
58.Years as a nurse practitioners 
 0-5 years 
 6-10 years 
 11-15 years 
 16-20 years 
 21-25 years 
 26-30 years 
 31-35 years 
 36-40 years 
 > 40 years 
 
59.Years since highest non-nursing degree awarded  
 0-5 years 
 6-10 years 
 11-15 years 
 16-20 years 
 21-25 years 
 26-30 years 
 31-35 years 
 36-40 years 
 > 40 years 
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60.Current age 
 20-25 years 
 26-35 years 
 36-45 years 
 46-55 years 
 56-65 years 
 > 66 years 
 
61.Gender 
 Male 
 Female 
 
62.Race/Ethnicity 
 American Indian or Alaskan Native 
 Asian American 
 Black, not of Hispanic Origin 
 Hispanic 
 Native Hawaiian or Pacific Islander 
 White, not of Hispanic Origin 
 Other ____________________ 
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63.Nurse Practitioner Employment Setting 
 Ambulatory/outpatient/primary care office 
 Public health 
 Obstetric clinic 
 Retail clinic (e.g., Walgreen's', CVS) 
 Emergency department 
 Employee health clinic 
 Extended/long-term care facility 
 Skilled nursing facility 
 Home care, hospice, palliative care 
 Intensive care unit 
 In-patient hospital unit/hospitalist 
 Occupational health 
 Wellness center 
 Educational (please specify if it is an  associate, diploma, bachelor or higher degree 
program) ____________________ 
 Non-tradition setting (specify) ____________________ 
 Other setting (specify) ____________________ 
 
64.Specialized practice setting 
 Vascular/cardiology 
 Pulmonary 
 Oncology 
 Pediatric 
 Family Practice 
 Women Health/ OB/GYN 
 Genetic/Genomic 
 Dermatology 
 Gastroenterology 
 Renal 
 Neonatal 
 Psychiatry 
 Adult/Gerontology 
 other (specify) ____________________ 
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65.Site 
 Urban area (50,000 or more population) 
 Urban cluster (suburban, 2,500 to less than 50,000 population) 
 Rural (less than 2,500 population) 
 Other (specify) ____________________ 
 
66.Employment status 
 Full-time (40 or more hours/week) 
 Part-time ( less than 40 hours/week) 
 Per diem 
 Retired 
 Disabled 
 Seeking employment 
 Not seeking employment 
 
67.How many courses in your formal NP education integrated genetics/genomics in the 
course content? 
 0 
 1 
 2 
 3 
 >3 
 
68.How many courses in your non-nursing education integrated genetics/genomics in the 
course content? 
 0 
 1 
 2 
 3 
 >3 
 
69.Local South Carolina professional nurse practitioner association membership (check 
all that apply) 
 Low Country Nurse Practitioner Association 
 Upstate Nurse Practitioner Association 
 None 
 Other (specify) 
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70.South Carolina state nurse practitioner association membership (check all that apply) 
 American Nursing Association chapter (SCANA) 
 Other (specify) ____________________ 
 None 
 
71.National nurse practitioner association membership (check all that apply) 
 American Association of Nurse Practitioners (AANP) 
 National Organization of Nurse Practitioner Faculties (NONPF) 
 National Association of Nurse Practitioners in Women's Health (NPWH) 
 National Association of Pediatric Nurse Practitioners (NAPNAP) 
 National Conference of Gerontological Nurse Practitioners (NCGNP) 
 Nurse Practitioner Associates of Continuing Education (NPACE) 
 Uniformed Nurse Practitioner Association (UNPA) 
 Other (specify) ____________________ 
 
72.Membership in a professional organization that has a special interest in 
genetics/genomics (check all that apply) 
 International Society of Nurses in Genetics (ISONG) 
 Oncology Nursing Society - Special Interest Group (ONS SIG) 
 Other (specify) ____________________ 
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Appendix C 
 
Invitation to Take Questionnaire 
 
 
Dear South Carolina Nurse Practitioner, 
 
As a member of one of the South Carolina nurse practitioner associations, I am inviting 
nurse practitioners, who are members in a South Carolina nurse practitioner association, 
to pilot test my dissertation research online questionnaire, “Development of an Online 
Questionnaire to Assess Awareness of the Genetic Information Nondiscrimination Act of 
2008 (GINA) in Nurse Practitioners”. E-mail addresses were received from the various 
nurse practitioner associations in South Carolina.  Once the survey has been distributed, 
all e-mail addresses will be destroyed. 
 
As compensation for your time to complete this questionnaire, your e-mail address will 
be entered for a chance to have your 2014 membership dues paid.  Four members from 
each nurse practitioner association in South Carolina will be randomly chosen from 
questionnaire respondents to have their dues paid.  Once the nurse practitioners who will 
receive the membership dues have been randomly chosen, the questionnaires will be de-
identified so that all responses will be anonymous during review and data analyses. 
 
Please read the attached informed consent.  After reading the informed consent, please go 
to the link provided to complete the questionnaire.  It is anticipated that questionnaire 
completion will take about 20 minutes of your time. 
 
Thank you very much for your participation in this study. 
 
Sincerely, 
Mary Beth Steck, PhD (c), APRN, BC 
Interdisciplinary PhD in Healthcare Genetics 
Clemson University 
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Appendix D 
 
IRB Approval Letter for Focus Group 
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Appendix E 
IRB Approval Letter for Content Expert Group 
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Appendix F 
 
IRB Approval Letter for Field Testing Questionnaire 
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Appendix G 
 
IRB Approval Letter for Pilot Study 
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Appendix H 
 
IRB Approval Letter for Extension 
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Appendix I 
 
Innovativeness Scale Guidelines 
An innovation is an idea, practice, or object that is perceived as new by an    
individual or other unit of adoption (like an organization). People and 
organizations vary a great deal in their "innovativeness." Innovativeness has to 
do with how early in the process of adoption of new ideas, practices, etc. that the 
individual or organization is likely to accept a change. 
 
The individual innovativeness scale was designed to measure individuals' 
orientations toward change. Research has indicated that this orientation is 
associated with several communication variables. The II instrument has been 
found to be highly reliable and the predictive validity is good. 
 
Directions: People respond to their environment in different ways. The statements 
below refer to some of the ways people can respond. Please indicate the degree to 
which each statement applies to you by marking whether you: Strongly Disagree = 1; 
Disagree = 2; are Neutral = 3; Agree= 4; Strongly Agree = 5 Please work quickly, 
there are no right or wrong answers, just record your first impression. 
 
  1. My peers often ask me for advice or information. 
 
  2. I enjoy trying new ideas. 
 
  3. I seek out new ways to do things. 
 
______4. I am generally cautious about accepting new ideas. 
 
______5. I frequently improvise methods for solving a problem when an answer is not 
apparent.
 
 6. I am suspicious of new inventions and new ways of thinking. 
 
  7. I rarely trust new ideas until I can see whether the vast majority of people 
around me accept them. 
 
  8. I feel that I am an influential member of my peer group. 
 
  9. I consider myself to be creative and original in my thinking and behavior.
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  10. I am aware that I am usually one of the last people in my group to accept 
something new. 
 
  11. I am an inventive kind of person. 
 
  12. I enjoy taking part in the leadership responsibilities of the group I belong to. 
 
  13. I am reluctant about adopting new ways of doing things until I see them 
working for people around me. 
 
  14. I find it stimulating to be original in my thinking and behavior. 
 
  15. I tend to feel that the old way of living and doing things is the best way. 
 
  16. I am challenged by ambiguities and unsolved problems. 
 
  17. I must see other people using new innovations before I will consider them. 
 
  18. I am receptive to new ideas. 
 
  19. I am challenged by unanswered questions. 
 
  20. I often find myself skeptical of new ideas. 
 
Scoring: 
 
Step 1: Add the scores for items 4, 6, 7, 10, 13, 15, 17, and 20. 
Step 2: Add the scores for items 1, 2, 3, 5, 8, 9, 11, 12, 14, 16, 18, and 19. 
Step 3: Complete the following formula: II = 42 + total score for Step 2 - total score for 
Step 4: Scores above 80 are classified as Innovators. 
Scores between 69 and 80 are classified as Early 
Adopters. Scores between 57 and 68 are classified as 
Early Majority. Scores between 46 and 56 are 
classified as Late Majority. Scores below 46 are 
classified as Laggards/Traditionalists. 
In general people who score above 68 and considered highly innovative, and people 
who score below 64 are considered low in innovativeness. 
 
Source: 
Hurt, H. T., Joseph, K., & Cook, C. D. (1977). Scales for the measurement of 
innovativeness. Human Communication Research, 4, 58-65. 
 
